



**HAL**  
open science

# Probabilistic Cellular Automata modeling of intercellular interactions in airways: complex pattern formation in patients with Chronic Obstructive Pulmonary Disease

Isabelle Dupin, Edmée Eyraud, Élise Maurat, Jean-Marc Sac-Épée, Pierre Vallois

## ► To cite this version:

Isabelle Dupin, Edmée Eyraud, Élise Maurat, Jean-Marc Sac-Épée, Pierre Vallois. Probabilistic Cellular Automata modeling of intercellular interactions in airways: complex pattern formation in patients with Chronic Obstructive Pulmonary Disease. *Journal of Theoretical Biology*, 2023, pp.111448. 10.1016/j.jtbi.2023.111448 . hal-03572045v2

**HAL Id: hal-03572045**

**<https://hal.science/hal-03572045v2>**

Submitted on 12 Oct 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Probabilistic Cellular Automata modeling of intercellular  
2 interactions in airways : complex pattern formation in  
3 patients with Chronic Obstructive Pulmonary Disease

4 Isabelle Dupin<sup>1,2</sup>, Edmée Eyraud<sup>1,2</sup>, Élise Maurat<sup>1,2</sup>, Jean-Marc Sac-Épée<sup>3</sup>  
and Pierre Vallois<sup>3\*</sup>

<sup>1</sup> Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux,  
U1045, F-33000 Bordeaux, France

<sup>2</sup> INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045,  
F-33000 Bordeaux, France

<sup>3</sup> Université de Lorraine, CNRS, Inria, IECL. F-54000 Nancy, France

---

\*Email corresponding author : [isabelle.dupin@u-bordeaux.fr](mailto:isabelle.dupin@u-bordeaux.fr))

1 **Highlights**

2

- 3 — Probabilistic Cellular Automata models fibrocytes and CD8+ T cells interplay.  
4 — The parameters are estimated accurately from theoretical analysis and experiments.  
5 — The dynamics of cell populations is simulated within lungs over 20 years.  
6 — Two distinct patterns emerge, corresponding to the healthy and COPD situations.

1 **Abstract**

2 The chronic obstructive pulmonary disease (COPD) is a highly prevalent lung disease, in  
3 which unusual interactions between fibrocytes and CD8+ T lymphocytes in the peribronchial  
4 area could induce chronic inflammation and tissue remodeling. We considered a probabilistic  
5 cellular automata type model where the two types of cells follow simple local interaction rules  
6 taking into account cell death, proliferation, migration and infiltration. A rigorous mathe-  
7 matical analysis carried out within the framework of a streamlined model makes it possible  
8 to estimate with precision the parameters of the model using multiscale experimental data  
9 obtained in control and disease conditions. The simulation of the model is simple to be imple-  
10 mented. In simulations, two distinct patterns emerged, which can be analyzed quantitatively.  
11 In particular, we show that the change in fibrocyte density in the COPD condition is mainly  
12 the consequence of their infiltration into the lung during exacerbations, suggesting possible  
13 explanations for experimental observations in normal and COPD tissue. Our integrated ap-  
14 proach combining probabilistic cellular automata type model and experimental findings will  
15 provide further insights into COPD in future studies.

16 **Keywords :**

17 Fibrocytes, lymphocytes, chronic respiratory disease, local environment, Markov process, chro-  
18 nic inflammation.

19

20 **Fundings**

21 This study was supported by a grant from the "Fondation Bordeaux Université", with funding  
22 from "Assistance Ventilatoire à Domicile" (AVAD) and "Fédération Girondine de Lutte contre  
23 les Maladies Respiratoires" (FGLMR).

24 **Declaration of interest** ID have a patent (EP N°3050574 : Use of plerixafor for treating  
25 and/or preventing acute exacerbations of chronic obstructive pulmonary disease) granted. All  
26 other authors declare they have no competing interests.

# 1 Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory disease that affects adults over 40 years of age. The major risk factor is exposure to aerosolized pollutants, such as cigarette smoke. Patients with COPD often experience "exacerbations", which are periods of acute worsening of their respiratory symptoms. Exacerbations play an important role in the progression of the disease. COPD is characterized by chronic bronchial inflammation of the airways and parenchyma.

Changes in the structure of the tissue are also observed, such as lamina propria fibrosis of the so-called "distal" bronchi, i.e. bronchi with a lumen diameter of less than 2 mm, leading to persistent airflow obstruction ([20]). The understanding of the pathophysiological mechanisms of COPD has progressed thanks to animal models ([11]), in vitro studies ([23]), and expression analyses using bulk human lung tissue ([24]) and more recently at the single cell level ([2]). However, detailed knowledge of the crosstalks among multiple lung cell types and particularly their evolution along COPD development is still lacking, and treatments for COPD have seen minimal advances over the past decades ([52]).

The bronchial wall is a complex structure, and comprises different cell types, including both structural cells, such as fibrocytes and fibroblasts, and immune cells, such as lymphocytes and dendritic cells. These non-epithelial cells are sparse and they embedded in an extracellular matrix, which maintains the three-dimensional architecture of the lung by interconnecting cells, that do not adhere tightly to each other ([22]). Bronchi of COPD patients are infiltrated with a large amount of lymphocytes, and in particular CD8+ T cells. The density of CD8+ T cells in lung parenchyma and small airways inversely correlates with lung function, ([37]), suggesting the implication of CD8+ T cells in deleterious COPD evolution. On the other hand, we have previously shown in [6] that fibrocytes, circulating cells with fibroblastic properties, were present in increased levels in the blood of COPD patients at the time of an exacerbation and increased densities in the bronchi of COPD patients ([7]).

The deregulation of interactions between immune (including CD8+ T cells) and non-immune (including fibrocytes) cells could be a hallmark of chronic inflammation and tissue remodelling. In particular, it was recently shown that fibrocytes could interact with CD8+ T cells and promote their proliferation ([1]), suggesting that the interplay between these two cell types could play a role in COPD onset and evolution.

Nevertheless, we are very far from understanding how the system works at the population and tissue levels. Moreover, it is also difficult to know how the disease disrupts this system. Our working hypothesis is the following : modifications of the local interactions between fibrocytes and CD8+ T cells are the trigger to alter spatial distribution of cells, corresponding to the pathological state. This hypothesis is very difficult to test experimentally. *In vivo* progressive airflow obstruction is a complex and progressive process and an ideal model should take into account all types of cells and the associated cellular events. Therefore, we decided to build a mathematical model that only includes processes related to fibrocytes and CD8+ T cells, on which information can be drawn from experimental data.

The selected mathematical model and especially the simulations associated with it should allow to show how modifications of the local interaction rules lead to two distributions of fibrocytes and CD8+ T cells, that differ according to whether the subject considered is healthy or sick. Two-population mathematical models include deterministic models, which classically rely on predator-prey formulation. Deterministic models are particularly pertinent to describe biological systems such as tumorsphere growth. In these models, significant insights and equations

1 underlying system dynamics have been partially obtained from experimental data, see for ins-  
2 tance [3]. These models are particularly useful to describe the behaviour of the system at the  
3 population level, but do not take into account the interactions at the single cell-level. Spatial  
4 variables, critical features in our problematic to predict the tissular architecture, are usually  
5 lacking in deterministic models. This, such an approach does not sound very appropriate to  
6 model cellular crosstalk in the peri-bronchial area, where experimental data are very scarce  
7 and mostly relate to results obtained on individual-level interactions between fibrocytes and  
8 CD8+ T cells.

9 The individual nature of cells can be taken into account by agent-based models, which  
10 allow to derive more easily the interaction rules from experimental data. Off-lattice models,  
11 such as center-based (CBM) and deformable-cell (DCM) models, are continuous-space agent-  
12 based models that can be formulated using discrete time steps ([53], [36]) or continuous time  
13 ([38]). On-lattice models are spatially discrete models evolving in discrete time steps or in  
14 continuous time. For off-lattice as for on-lattice models, displacement of a cell is deterministic  
15 and completely defined by its velocity ([36]). Interactions between cells in off- and on-lattice  
16 models are taken into account by different types of velocity alignment. Thus, those models  
17 appear especially adapted to study the emergence of pattern formation in multicellular systems  
18 from velocity alignment interactions among cells. Among agent-based models, Lattice Gas  
19 Cellular Automaton models (see Sections 5.4 and 7 in [5]) relies on both the explicit description  
20 on agent position and its velocity. Those type of models could be relevant to our needs [16]  
21 but they are mainly used to model single and collective migration.

22 The framework of Probabilistic Cellular Automaton (PCA) seemed to us the most adapted  
23 to account for the local interactions of CD8+ T cells and fibrocytes. PCA are discrete-time  
24 agent-based models, in which the state of the agents evolve with time according to stochastic  
25 rules. One can find in the two monographs [5] and [30] the definition of these PCA and  
26 theoretical models. CA and PCA are widely applicable for modelling systems like forest spread  
27 ([32]), eco systems ([19]), natural patterns ([33]), neuronal networks ([42]), epidemic systems  
28 ([10]). PCA have also been used in life sciences, for example to study adult neurogenesis  
29 for teleost fishes in [28] and cell differentiation in [50]. Interestingly, previous agent-based  
30 computational approaches have been used in the field of lung science to describe the allergic  
31 inflammatory response ([39] and [40]) and airway remodelling in asthma ([44]). Thus, we  
32 decided to use PCA to model macroscopic behavior starting from microscopic interaction  
33 rules governing fibrocytes and CD8+ T cells behaviours. In contrast to "classical" PCA, which  
34 evolves synchronously in discrete time and in which the updating concerns all the cells, we have  
35 made the cells evolve one after the other as in [12] and [25]. The probability that a cell moves,  
36 dies or proliferates depends on the number of cells present in a nearby neighbourhood. We will  
37 be able to access qualitative estimates of these probabilities thanks to data from the literature  
38 and from experiments : for example, we will be able to compare the attraction/proliferation  
39 potential of CD8+ T cells purified from tissues/blood of healthy subjects or patients with  
40 COPD.

41 Let us briefly outline the organization of the paper. We describe in Section 2.1 the individual  
42 behavior of the CD8+ T cells and fibrocytes and their mutual dynamics is presented in Section  
43 2.1.10. We show that our model is Markovian and ergodic in Section 2.2. We assume that for  
44 a healthy subject as for a sick subject, the same model applies, but with different parameters.  
45 We introduce in Section 2.3 a streamlined model which is obtained for some specific values  
46 of the parameters. In this setting, a rigorous mathematical analysis makes it possible to both  
47 estimate the parameters and measure the quality of these estimates (see Section 3.1).

1 Our model can be simulated, we present in Section 3.2 some outputs of the simulations of  
 2 the streamlined model. The conclusion and discussion are found in Section 4. The proofs of  
 3 technical points are postponed in Section 5.

## 4 **2 Materials and methods**

### 5 **2.1 Model definition and notations**

#### 6 **2.1.1 General definition**

7 CD8+ T cells and fibrocytes are noted respectively in the following  $C$  and  $F$ .  
 8 The model takes into consideration cell displacement, death, proliferation and infiltration,  
 9 that occurs at the stable state and during exacerbation. Indeed,  $C$  and  $F$  cells have a limited  
 10 lifespan that depends on cell type and they can therefore be affected by cell death. When the  
 11 cells are alive,  $C$  cells can move and proliferate, whereas  $F$  can only move (see Section 2.1.5).  
 12 For the initial distribution, we used the mean density of non-smokers subjects, reflecting the  
 13 "healthy" situation.

14 As stated in the introduction, in our model there are two types of subjects : those who  
 15 are healthy and those who are affected by COPD. We make the assumption that these two  
 16 situations can be represented by the same model, but with different parameter values. To be  
 17 able to simulate the model, it is necessary to obtain numerical values for these parameters.  
 18 This will be achieved through biological experiments and data from literature. We denote by  
 19  $\gamma^{ctl}$  (resp.  $\gamma^{COPD}$ ) the value of the parameter  $\gamma$  for a healthy (resp COPD) subject.  
 20 All the parameters are defined below and summarized in Table 1 in Section 6.

#### 21 **2.1.2 Representation of the surface of interest**


22 We consider a lattice, of dimension  $103 \times 103$  where the area of each square is determined by  
 23 the size of a cell (Figure 1). A  $C$  cell has a diameter of about  $8 \mu m$  ([35] and our unpublished  
 24 observations), giving a surface area of  $50 \mu m^2$ . The size is roughly equivalent for a  $F$  cell.  
 25 Thus, the cells are modeled by squares with a side length  $x_0 = 7 \mu m$ , which correspond to the  
 26 units of the lattice. Each element of the lattice is defined by 2 coordinates, where the point  
 27 on the upper left (resp. lower right) corner has the coordinates  $(1, 1)$  (resp.  $(103, 103)$ ). The  
 28 coordinates of the center of the lattice are  $(52, 52)$ . The geometry of bronchi corresponds to  
 29 the transverse section of a cylinder, then we model our surface of interest, the peribronchial  
 30 (also called « lamina propria »), by a crown with a "hole" in the middle. The external and  
 31 internal radii of this crown are defined thanks to our measurements on the bronchial tissues :

- 32 1. the internal radius is  $263 \mu m$ , which represents the length of 38 lattice sites. This has  
 33 been calculated using our measurements of the corresponding disk (i.e. lumen area +  
 34 epithelium surface), which is on average  $216\ 567 \mu m^2$ .
- 35 2. The external radius is  $355 \mu m$ , which represents the length of 50 lattice sites. This has  
 36 been calculated using our measurements of the corresponding disk (i.e. lumen area +  
 37 epithelium surface + lamina propria), which is on average  $396\ 436 \mu m^2$ .

Then the lamina propria  $\mathcal{L}$  is the set of points with coordinates  $(i, j)$  such that :

$$38 \leq \widehat{d}((i, j), (52, 52)) \leq 50$$

1 where  $\hat{d}$  is the pseudo-distance :  $\hat{d}((i, j), (i', j')) = \lfloor \sqrt{(i - i')^2 + (j - j')^2} \rfloor$  and  $\lfloor x \rfloor$  stands  
2 for the integer part of the real number  $x$ . We thus obtain a working surface containing 3 652  
3 lattice sites (potential cells) corresponding to an area of approximately  $179\,000\ \mu\text{m}^2$ , which  
4 is in agreement with our *in situ* measurements. In other words, the number  $|\mathcal{L}|$  of elements  
5 of  $\mathcal{L}$  equals 3 652. Reflecting (zero-flux) boundary conditions are imposed at the external and  
6 internal borders. On each site, there is at most one cell.  
7 In the literature, it is described that bronchial wall thickness is increased in COPD patients,  
8 ([20], [15]) but we did not observe this increase in our tissue measurements. We will consider  
9 the area of the lamina propria to be the same for healthy subjects and patients with COPD.



10  
11 Figure 1. The lamina propria  $\mathcal{L}$  forms two 2-dimensional crown shape in the bronchial wall,  
12 between the bronchial epithelium and the smooth muscle layer. ECM : extracellular matrix.

13 We now fix some notations.

- 14 **Notation 2.1** 1. For any site  $(i, j) \in \mathcal{L}$ ,  $M(i, j)$  is the neighbourhood of  $(i, j)$ , it is the set  
15 of  $(i - 1, j - 1), (i - 1, j), (i - 1, j + 1), (i, j - 1), (i, j + 1), (i + 1, j - 1), (i + 1, j), (i + 1, j + 1)$   
16 belonging to  $\mathcal{L}$ . For a site inside the lamina propria the cardinal of  $M(i, j)$  is 8 and  
17 lower if this site is at the edge of  $\mathcal{L}$ . We will note in the following  $|M(i, j)|$  the number  
18 of elements of  $M(i, j)$ . In the literature, Moore's neighbourhood is  $M(i, j) \cup \{(i, j)\}$ .
- 19 2. A site of  $\mathcal{L}$  has the code 1 (resp. 2) if it contains a F (resp. C) cell. If the site is  
20 empty it will be coded 0. This state corresponds either to another cell type (mainly  
21 mesenchymal, that was hypothesized to interact minimally with fibrocyte and CD8+ T  
22 cells) or to extracellular matrix, which does not play any role in the cellular cross-talk.  
23 This is the predominant state, as the bronchial wall contains structural and immune  
24 cells sparsely embedded in the extracellular matrix.
- 25 3. A configuration is an element  $x = (x(i, j))_{(i, j) \in \mathcal{L}}$  where  $x(i, j)$  belongs to  $\{0, 1, 2\}$  and  
26  $x(i, j) = 1$  (resp.  $x(i, j) = 2$ ) means that a F (resp. C) cell occupies the site  $(i, j)$  and  
27  $x(i, j) = 0$  when the site  $(i, j)$  is empty. The set of configurations is  $\{0, 1, 2\}^{\mathcal{L}}$  and is  
28 identified with  $\{0, 1, 2\}^{|\mathcal{L}|}$ .
4. For any  $s = (i, j)$ ,  $V(F)(s)$  (resp.  $V(C)(s)$ ) denotes the number of F (resp. C) cells



near  $s$

$$V(F)(s) = \sum_{s' \in M(s)} 1_{\{x(s')=1\}}, \quad V(C)(s) = \sum_{s' \in M(s)} 1_{\{x(s')=2\}}.$$

$V(s)$  is the number of  $F$  and  $C$  cells close to  $s$  :

$$V(s) = V(F)(s) + V(C)(s) = \sum_{s' \in M(s)} 1_{\{x(s')=1 \text{ or } 2\}} = \sum_{s' \in M(s)} 1_{\{x(s') \neq 0\}}.$$

### 1 2.1.3 The initial cell distribution

For the initial distribution  $\nu_0$ , we first used the mean of the densities of  $C$  and  $F$  cells measured on tissues from non-smokers subjects, reflecting the “healthy” situation :

$$n_0(C) = 0.660 \times 10^{-3} \text{cells} / \mu\text{m}^2 \text{ and } n_0(F) = 0.106 \times 10^{-3} \text{ cells} / \mu\text{m}^2.$$

To obtain these densities with a lattice of 3 652 sites which represents an area of  $3\,652 \times 49 = 178\,948 \approx 179\,000 \mu\text{m}^2$ , we will therefore consider

$$\begin{aligned} N_0(C) &= 0.660 \times 10^{-3} \times 179\,000 \approx 118 \text{ } C \text{ cells} \\ N_0(F) &= 0.106 \times 10^{-3} \times 179\,000 \approx 19 \text{ } F \text{ cells.} \end{aligned} \tag{2.1}$$

- 2 Second we choose the  $N_0(C)$  (resp.  $N_0(F)$ )  $C$  (resp.  $F$ ) cells uniformly distributed in the  
 3 lamina propria.  
 4 Random spatial representations can be obtained with determinantal point processes. We have  
 5 not retained them because they rather model repulsive phenomenons and therefore they are  
 6 not adapted to our interaction model. Moreover their simulation is delicate, see [26].

### 7 2.1.4 Cell death

8  $C$  and  $F$  cells have a limited lifespan, which varies from cell to cell. When they are alive, they  
 9 will be able to move or duplicate as explained in the following sections. In our algorithm (see  
 10 Section 2.1.10), when a cell dies, it stays in place for a while and then disappears.

11 We suppose that a  $F$  cell has a probability  $p_{dF}$  of dying, see Figure S1.

12 We define for each  $C$  cell a "basal" probability  $p_{dC}$  of dying, and an increased probability  
 13  $p_{dC+}$  of dying when the  $C$  cell has many other  $C$  cells in its neighbourhood. We distinguish  
 14 two cases see Figure S1 :

- 15 1. if  $C$  cell has few  $C$  neighbours ( $V(C)(s) < \sigma$ , where  $\sigma$  is an unknown integer), then  
 16 this  $C$  cell attempts to die with the probability  $p_{dC}$
- 17 2. If  $C$  cell has many  $C$  neighbours ( $V(C)(s) \geq \sigma$ ), then  $C$  cell attempts to die with the  
 18 probability  $p_{dC+}$ .

19 The introduction of the probability  $p_{dC+}$  is justified by a recent study ([55]) showing the  
 20 existence of CD8+ T cell-population-intrinsic mechanisms regulating cellular behavior, with  
 21 induction of apoptosis to avoid an excessive increase in T cell population. Therefore, we defi-  
 22 ned  $\sigma$ , as the threshold number of neighbouring  $C$  cells, above which the probability of dying  
 23 for a  $C$  cell is increased from  $p_{dC}$  to  $p_{dC+}$ .

24 The numerical values of  $p_{dC}$ ,  $p_{dC+}$ ,  $\sigma$  and  $p_{dF}$  will be presented in Section 3.1.1.

25

1 **2.1.5 Proliferation of C cells**

2 Cells have the ability to duplicate. In our algorithm (see Section 2.1.10), when a cell  
 3 divides, it gives birth to 2 daughter cells, with one staying at the place of the mother cell,  
 4 and the other one being created in an empty site in the neighborhood of the mother cell. We  
 5 define for each  $F$  cell a probability  $p_F$  of dividing. Based on our own unpublished observations  
 6 and published studies ([29] and [46]), fibrocytes ( $F$  cells) very poorly proliferate in culture,  
 7 allowing us to consider that an  $F$  cell does not divide in lung tissue. We will thus consider  
 8 that a  $F$  cell does not proliferate, so we will take  $p_F = 0$ .

9 For each  $C$  cell, we define a "basal" probability  $p_C$  of dividing and an increased probability  
 10  $p_{C/F}$  of dividing when the  $C$  cell has  $F$  cell(s) in its neighbourhood. This latter probability  
 11 is justified as our unpublished results and those from another study ([1] et al., 2021) show a  
 12 robust and high increase of  $C$  cell proliferation in direct co-cultures of  $F$  and  $C$  cells.

13 Consider a  $C$  cell located in  $s$  (Figure S2). To reflect contact inhibition that enables cells to  
 14 stop proliferating when many of them are in contact with each other, we also introduce the  
 15 threshold number  $\lambda$ , such that the proliferation of  $C$  does not occur if for any  $s'$  neighbouring  
 16  $s$ , the number of  $C$  cells exceeds  $\lambda$ .

- 17 1. In the following two cases
- 18 (a) all sites in  $M(s)$  are occupied (i.e.  $V(s) = |M(s)|$ )
  - 19 (b) if all empty  $s'$  sites belonging to  $M(s)$  have "many"  $C$  neighbours (i.e.  $V(C)(s') \geq \lambda$ ,  
 20 where  $\lambda$  is an integer to be specified)
- 21 the  $C$  cell does not divide.
- 22 2. There exists at least one empty site  $s' \in M(s)$  such that  $V(C)(s') < \lambda$ .
- 23 (a) If there is no  $F$  cell in  $M(s)$ , the  $C$  cell attempts to divide with the probability  $p_C$ .
  - 24 (b) If there is at least one  $F$  cell in  $M(s)$ , the  $C$  cell attempts to divide with the  
 25 probability  $p_{C/F}$ .
- 26 If proliferation occurs, we decide that  $C$  remains in  $s$  and we uniformly choose an  
 27 unoccupied site  $s'$  belonging to  $M(s)$ , such that  $V(C)(s') < \lambda$ , on which we create a  
 28 new cell.

Since in the absence of stimulation, the major part of  $C$  cells do not divide in the lung ([18]), we will therefore consider that in the absence of any other stimulation, the probability  $p_C$  that a  $C$  cell divide in the peribronchial area is zero, for control subjects as well as COPD patients :

$$p_C^{ctl} = p_C^{COPD} = 0. \tag{2.2}$$

Previous studies indicate that the doubling time of  $C$  cells *in vivo* after a stimulation such as a contact with a fibrocyte is estimated around  $4h$  ([54], [27]). We will consider an average duration of  $4h = 80 \times 3min$  for a cell cycle of a  $C$  cell when a  $F$  cell is in its close environment. For healthy subjects, the increased probability  $p_{C/F}$  of dividing will therefore be taken equal to  $1/80$ . This probability is identical for control subjects and COPD patients :

$$p_{C/F}^{ctl} = p_{C/F}^{COPD} = 1/80 = 1.25 \times 10^{-2}. \tag{2.3}$$

### 1 2.1.6 Displacement of $C$ and $F$ cells

$C$  and  $F$  cells are able to move, as shown previously ([6], [35]). This process is taken into account in the model, as described below.

Let  $s = (i, j)$  and  $s' = (i', j')$  be two sites of the lamina propria. A cell can only move to a site adjacent to the occupied site :

$$P_F(s, s') = P_C(s, s') = 0 \text{ if } s' \notin M(s) \cup \{s\} \text{ or } s' \in M(s) \text{ and is occupied}$$

where  $P_F(s, s')$  (resp.  $P_C(s, s')$ ) denotes the probability that a  $F$  (resp.  $C$ ) cell has to move from  $s$  to  $s'$ .

Our chemotaxis experiments show that  $F$  cells are significantly attracted towards the secretion of  $C$  cells, whatever the condition of the subject (control or COPD). This leads us to take

$$P_F(s, s') = \begin{cases} k_F f_F(V(C)(s')) & \text{if } s' \in M(s) \text{ and } s' \text{ is empty} \\ k_F x_F & \text{if } s' = s \end{cases} \quad (2.4)$$

where  $x_F > 0$ ,  $f_F$  is a function defined on  $\{0, 1, 2, \dots, 8\}$  taking positive values and

$$k_F = \frac{1}{x_F + \sum_{s' \in M(s)} f_F(V(C)(s')) 1_{\{s' \text{ empty}\}}} \quad (2.5)$$

is the normalization factor such that  $P_F(s, \cdot)$  is a probability.

Since this chemotactic effect requires soluble factors that have to be secreted in a sufficient concentration, this justifies an almost zero attraction ( $\epsilon_F > 0$  "small", arbitrarily chosen as  $\epsilon_F = 10^{-3}$ ) for  $s'$  such as  $V(C)(s') < 3$  cells and a maximal and constant attraction for  $s'$  such as  $V(C)(s') = 3$  or 4 cells. On the other hand, the attraction of the site  $s'$  for a  $F$  cell probably decreases when the site is too "crowded", because of physical hindrance and/or the secretion of factors that are secreted when many  $C$  cells are aggregated. For control subjects, we have thus chosen  $f_F^{ctl}(n) = 1$  (resp.  $f_F^{ctl}(n) = \epsilon_F$ ) if  $n \in \{3, 4\}$  (resp.  $n \in \{0, 1, 2, 5, 6, 7, 8\}$ ). Our chemotaxis experiments show that secretions from  $C$  cells isolated from parenchyma of COPD patients are more attractive for  $F$  cells than those of  $C$  cells isolated from control patients, indicating that a smaller number of  $C$  cells is required to attract  $F$  cells in pathological condition than in healthy situation. For patients with COPD, we have thus chosen :  $f_F^{COPD}(n) = 1$  (resp.  $f_F^{COPD}(n) = \epsilon_F$ ) if  $n \in \{2, 3, 4\}$  (resp.  $n \in \{0, 1, 5, 6, 7, 8\}$ ).

We now consider the case of a  $C$  cell alive and occupying the site  $s$ . It will move to the site  $s' \in M(s) \cup \{s\}$ , with probability

$$P_C(s, s') = \begin{cases} k_C f_C(V(s')) & \text{if } s' \in M(s), s' \text{ is empty} \\ k_C x_C & \text{if } s' = s \end{cases} \quad (2.6)$$

with  $x_C > 0$ ,  $f_C$  is a function defined on  $\{0, 1, 2, \dots, 8\}$  taking positive values and

$$k_C = \frac{1}{x_C + \sum_{s' \in M(s)} f_C(V(s')) 1_{\{s' \text{ empty}\}}} \quad (2.7)$$

- 2 is the normalization factor such that  $P_C(s, \cdot)$  is a probability.
- 3 Based on the same type of justifications than those used for  $F$  cells,  $f_C^{ctl}$  is the function defined
- 4 on  $\{0, 1, 2, 5, 6, 7, 8\}$  such that  $f_C^{ctl}(n) = 1$  (resp.  $f_C^{ctl}(n) = \epsilon_C$  where  $\epsilon_C = 10^{-3}$ ) if  $n \in \{4, 5\}$
- 5 (resp.  $n \in \{0, 1, 2, 3, 6, 7, 8\}$ ). We will consider that  $f_C$  is identical in control subjects and
- 6 COPD patients, leading to  $f_C^{ctl} = f_C^{COPD}$ , see Figure S4.
- 7 The values of  $x_F$  and  $x_C$  will be determined in Section 3.1.2.

8

### 1 2.1.7 Infiltration of $C$ and $F$ cells at the stable state

2  $F$  and  $C$  cells can infiltrate the lungs at the stable state, as justified below.  
3  $F$  cells have a limited lifespan in the lungs, with a half-life that we have estimated at 10 months  
4 in the lung, by analogy with the half-life of interstitial macrophages ([47]). Our previous work  
5 (cf [7]) indicates presence of  $F$  cells in the lungs, at varying densities in control subjects and  
6 COPD patients, suggesting infiltration of  $F$  cells at stable state, in order to maintain this  
7 pulmonary pool relatively constant. This leads us to add  $F$  cells, for an healthy subject as for  
8 a COPD subject, to reflect infiltration into the lungs at the stable state.  
9 Since  $C$  cells have a limited lifespan in the airways, with an estimated half-life of 14 days in  
10 the lung ([34]), it has been proposed that the number of memory  $C$  cells in the lung tissue is  
11 maintained through continuous recruitment ([8] and [51]).  
12 We will add at the beginning of each  $3mn$  time step, one  $F$  (resp.  $C$ ) cell with probability  
13  $p_{istaF}$  (resp.  $p_{istaC}$ ) to take into account the phenomenon of infiltration during the stable state.  
14 These probabilities will be determined from biological considerations (see Section 3.1.3). The  
15 choice of the value of  $3mn$  will be justified later in Section 2.1.9. If a cell is recruited, we  
16 randomly and uniformly position it among the empty sites. If there are no empty sites, no cell  
17 is added.

### 18 2.1.8 Infiltration of $F$ and $C$ cells during exacerbations

19 The process of infiltration can be amplified during exacerbations, which is an acute event  
20 specific of patients with COPD, and which is not happening in healthy subjects.  
21 Concerning  $F$  cells, in COPD patients, there is an increase in the concentration of  $F$  cells in  
22 the blood during exacerbations ([6]). In the lungs, the density of  $F$  cells is higher in tissues  
23 of COPD patients than in those of healthy subjects ([7]), suggesting that for COPD patients,  
24  $F$  cells are recruited from the blood to the lungs at the time of exacerbations. The average  
25 frequency of exacerbations is one per year in patients with COPD ([21]). To take into account  
26 the excess of  $F$  cells infiltration during this particular event, we will add, each year, a number  
27  $N(iexaF)$  of  $F$  cells, with the probability  $p_{iexaF}$  so that after 20 years, on average, the number  
28 of  $F$  cells in COPD patients is double than in healthy patients. If cells are added, they are  
29 placed uniformly on the empty sites of the lamina propria.

30  
31 Concerning  $C$  cells, the literature shows that there is probably an infiltration of  $C$  cells  
32 in the lungs, especially in COPD patients ([9] and [43]), but whether this infiltration occurs  
33 during exacerbations is not entirely clear. A study evidences an increased level of CD8+ T  
34 cells in the blood during exacerbations, which is interpreted as extravasation of CD8+ T cells  
35 towards sites of inflammation and lymphoid organs ([9]), while another publication highlights  
36 an increased number of CD8+ T cells in the blood of COPD patients during exacerbation  
37 ([4]). In a mice model of viral exacerbation, an increase of up to 5 times in the number of lung  
38 CD8+ T cells was observed 4 days after infection, before quickly returning to normal 6 days  
39 after infection ([8]). Overall, there therefore seems to be an infiltration of CD8+ T cells during  
40 exacerbations, however this infiltration seems to be very transient. For simplification, we will  
41 assume that there is no  $C$  cell infiltration during exacerbations. Thus, for a healthy subject  
42 as well as for a patient with COPD the value of  $p_{iexaC}$  is zero.

1 **2.1.9 The different time scales**

Let  $v_0$  be the median speed of a  $C$  cell measured in lung tissue during 15 minutes, and its value has been fixed accordingly to experimental measurements ([35]). In this study, CD8+ T cells have been imaged and tracked in mice lungs using two-photon live imaging. During the 15 min time frame which is typically used to analyze T cell movement, CD8+ T cells have been found to move at a median speed of  $2.3 \mu m/mn$ . This value is also consistent with other experimental measurements ([17]). Therefore, we choose :

$$v_0 = 2.3 \mu m/mn. \tag{2.8}$$

Since we have no information on the *in vivo* speed of a  $F$  cell, we will assume that its speed is identical to that of a  $C$  cell. For an idealized cell modeled by a square with a side length  $x_0 = 7 \mu m$ ,  $v_0$  thus represents approximately a movement of one square (lattice site) every  $t_0 = 3$  minutes. We therefore set the duration of a time step to 3 min.

The time steps are denoted  $k$ , where  $1 \leq k \leq T$  and  $T$  is the time it takes between the beginning of cigarette smoke exposure and the onset of the disease. The development of COPD takes several decades ([31]), we therefore choose arbitrary  $T$  equal to 20 years. As the time step in our model is  $3min$ ,  $T$  is expressed in iterations, and the value of  $T$  is :

$$T = 20 \times 365 \times 24 \times 20 = 3\,504\,000 \text{ iterations}$$

2 To take into account cell death, proliferation, displacement, duplication of cells we use the  
 3 procedure given in Section 2.1.10 : we divide each time step  $k$  in  $N_k$  sub-time steps, where  $N_k$   
 4 is the number of cells at the beginning of time step  $k$ . At each sub-time step, a cell is drawn  
 5 at random and can die, proliferate or move. We will consider more finely that  $v_0$  is a median  
 6 in Proposition 3.2.


7 **2.1.10 The dynamics of  $C$  and  $F$  cells**

8 Let us consider the beginning of the time step  $k + 1$ . There are  $N_k(F)$   $F$  cells and  $N_k(C)$   
 9  $C$  cells, then  $N_k = N_k(C) + N_k(F)$ . If a  $C$  or  $F$  cell is added by infiltration at the stable state  
 10 (cf subsection 2.1.7) we consider however that it is not part of the  $N_k$  initial cells, and cannot  
 11 be drawn at random afterwards. It is therefore neither subject to death, nor to proliferation,  
 12 nor to displacement during the time step  $k + 1$ , it is just considered as present.

13 We divide the time step  $k + 1$  into  $N_k$  sub-time steps. For each sub-time step, we randomly  
 14 draw a cell among the  $N_k$  present (with the probability  $1/N_k$ ). Several cases can occur.

- 15 1. If the selected cell is dead or if it is a  $C$  cell that gave birth to a new cell by proliferation  
 16 in a previous sub-time step, nothing happens.
- 17 2. Assuming in the following that the selected cell is alive and is not a "mother" cell, we  
 18 denote by  $(i, j)$  the site occupied by this cell. The cell attempts to die following the  
 19 procedure described in Subsection 2.1.4.
- 20 3. Suppose that the randomly drawn cell does not die.  
 21 (a) If the selected cell is  $F$ , it moves according to the rule described in Section 2.1.6.  
 22 (b) If it is a  $C$  cell,  
 23 i. it divides according to the procedure described in Section 2.1.5. If the cell prolifere-  
 24 rates, we consider that the cell that has been added is not part of the population  
 25 of  $N_k$  cells ;

- 1           ii. otherwise, it moves according to the rule described in Section 2.1.6.
- 2   When the  $N_k$  subtime steps have been repeated independently we add to the initial population
- 3   cells that are either born by proliferation or recruited by infiltration. Dead cells are removed.
- 4   The number of cells is then  $N_{k+1}$ . We start a new cycle of  $N_{k+1}$  sub-time steps, as previously
- 5   described. Therefore, over a time step, a given cell will on average die, move or divide (if it is
- 6   a  $C$  cell).
- 7   Infiltration during exacerbation : Every year, i.e. after 175 200 time steps, we add a number
- 8    $\overline{N}(iexaF)$  of  $F$  cells with the probability  $p_{iexaF}$ . If  $F$  cells are recruited by infiltration during
- 9   an exacerbation, they are randomly and uniformly positioned among all of the vacant sites.
- 10   Cells that have infiltrated in the meantime are added to the initial population. A new time
- 11   step starts again as described above.



12

13   Figure 2. Algorithm defining cell infiltration, death, proliferation and displacement of cells at

14   each time step. We consider the beginning of the time step  $k + 1$ . This period is divided into

15    $N_k$  sub-time steps, where  $N_k$  is the number of cells at the beginning of period  $k + 1$ .  $F$  and  $C$

1 cells are indicated by respectively green and purple squares.

## 2 2.2 Markov property

3 We start by setting some notations.

4 **Definition 2.2** 1. For any  $k$  belonging to  $\{1, \dots, T\}$ ,  $X_k = (X_k(i, j))_{(i, j) \in \mathcal{L}}$  represents  
5 the state of the lamina propria at the end of the  $k$  time step. According to item 3 of  
6 Notation 2.1,  $X_k(i, j) = 1$  (resp.  $X_k(i, j) = 2$ ) means that a  $F$  (resp.  $C$ ) cell occupies  
7 the site  $(i, j)$  and  $X_k(i, j) = 0$  when the site  $(i, j)$  is empty.  $X_k$  is a random variable  
8 which takes its values in  $\{0, 1, 2\}^{\mathcal{L}}$ .

9 2.  $\nu_0$  is the distribution of the initial state  $X_0$ , its value will be given in Section 2.1.3

10 3. Let  $N_k(C)$  (resp.  $N_k(F)$ ) be the number of  $C$  (resp.  $F$ ) cells at the end of time step  $k$ .

11 We adopt the notations used in the theory of random processes : for any initial probability  $\mu$   
12 on  $\{0, 1, 2\}^{\mathcal{L}}$ ,  $\mathbb{P}_\mu$  represents the probability under which the law of  $X_0$  is  $\mu$ .

13 **Proposition 2.3**  $(X_k)_{k \geq 0}$  is a recurrent, irreducible, a-periodic Markov chain that admits an  
14 unique invariant probability  $\nu$ .

**Proof.** Note that

$$N_k(F) = \sum_{(i, j) \in \mathcal{L}} 1_{\{X_k(i, j)=1\}}, \quad N_k(C) = \sum_{(i, j) \in \mathcal{L}} 1_{\{X_k(i, j)=2\}}.$$

15 Therefore, if  $x = X_k$  is known, the quantities  $N_k(F)$  and  $N_k(C)$  are fixed, as well as the  
16 composition of each neighbourhood. It is then possible to write  $X_{k+1} = F(X_k, \xi)$ , where  $F$  is  
17 a function and  $\xi = (\xi_i)_{i \geq 1}$  is a sequence of independent random variables and with uniform  
18 law on  $[0, 1]$ , independent of  $X_k$ . The Markovian property is immediately deduced from this.  
19 It is straightforward to prove that the Markov chain is recurrent and irreducible. Since  $\mathbb{P}_x(X_1 =$   
20  $x) > 0$ , for any  $x$ , it is a-periodic. Therefore  $(X_k)_{k \geq 0}$  admits a unique invariant probability. ■

21 To obtain the equilibrium state during simulations, one could think of using the Protz algo-  
22 rithm which allows to carry out exact simulations, see the seminal paper [41]. The lamina  
23 propria has a finite number of sites but too many (3 652), this algorithm only works when a  
24 "sandwiching" hypothesis is realized, see Chap. 11 in [13]. Unfortunately, in our context this  
25 assumption is not satisfied.

**Corollary 2.4** Let  $\mu$  be an initial law on  $\{0, 1, 2\}^{\mathcal{L}}$ . The two sequences of random variables  
 $(N_k(F))_{k \geq 0}$  and  $(N_k(C))_{k \geq 0}$  converge in law when  $k$  tends to infinity. Moreover there is  
convergence of the means :

$$\lim_{k \rightarrow \infty} \mathbb{E}_\mu(N_k(F)) = \mathbb{E}_\nu(N_0(F)), \quad \lim_{k \rightarrow \infty} \mathbb{E}_\mu(N_k(C)) = \mathbb{E}_\nu(N_0(C)).$$

26 **Proof.** We only deal with  $F$  cells. Note that  $\mathbb{P}_\mu(N_k(F) = l) = \mathbb{P}_\mu(X_k \in A(l, F))$ , where  
27  $l$  is an integer and  $A(l, F) = \left\{ x, \#\{(i, j) \in \mathcal{L}, \text{ such that } x(i, j) = 1\} = l \right\}$ . We deduce the

1 convergence in law of  $N_k(F)$ , as  $k \rightarrow +\infty$ . Moreover :

$$\begin{aligned} \lim_{k \rightarrow \infty} \mathbb{E}_\mu(N_k(F)) &= \lim_{k \rightarrow \infty} \left( \sum_{l=0}^{|\mathcal{L}|} l \mathbb{P}_\mu(X_k \in A(l, F)) \right) \\ &= \sum_{l=0}^{|\mathcal{L}|} l \mathbb{P}_\nu(X_k \in A(l, F)) = \mathbb{E}_\nu(N_k(F)) = \mathbb{E}_\nu(N_0(F)). \end{aligned}$$

2 ■

3 Since we are interested in a large number of periods  $T \approx 3.5 \times 10^6$  time-steps, we can consi-  
4 der that the Markov chain has reached its stationary state. This state depends only on the  
5 parameters and is independent from the initial distribution of cells.

### 6 **2.3 The streamlined model**

The streamlined model is a special case of the model, where local interactions, *i.e.*  $C$  cell-  
induced cell death and contact inhibition of  $C$  cell proliferation play no role. To reflect these  
two properties,  $\sigma$  and  $\lambda$  have been fixed respectively to 9 and 0. In the streamlined model, the  
probability  $p_C$  that a  $C$  cell divide is zero (see justification below). In the streamlined model  
the parameters are :

$$\sigma = 9, \quad p_C = 0, \quad \lambda = 0. \tag{2.9}$$

7 This means that  $C$  and  $F$  cell displacement, the stable infiltration and that due to exacer-  
8 bations (see Section 2.1.7, resp. 2.1.8) are identical to those in the complete model. However,  
9  $C$  cells do not proliferate at all (*i.e.*  $p_C = 0$  and  $\lambda = 0$ ) and die with the probability  $p_{dC}$   
10 independently of the local context ( $\sigma = 9$ ).

11 Since the streamlined model is a special case of the interaction model, the results of Section  
12 2.2 apply. In particular, the streamlined model is Markovian.

13 The major interest of the streamlined model is that it allows a rigorous mathematical analy-  
14 sis to accurately calculate parameters such as  $v_0$ ,  $p_{dC}$ ,  $p_{dF}$ ,  $x_C$ ,  $x_F$ ,  $p_{istaC}$ ,  $p_{istaF}$ ,  $p_{iexaF}$  and  
15  $N_{iexaF}$ .

16 We now justify the choice  $p_C = 0$ . Indeed, the cell cycle length of a  $C$  cell is highly variable,  
17 and it is difficult to obtain quantitative data at steady state. In so-called "nonlymphoid"  
18 tissues, such as the peribronchial area, activated  $C$  cells are unable to divide, although they  
19 are able to do so *in vitro* in response to the same antigenic stimulus ([14]). After primary  
20 viral infection, a minor part of the memory  $C$  cells continues to proliferate in the secondary  
21 lymphoid organs after resolution of the infection, and are recruited in the lungs, which makes  
22 it possible to ensure a relatively constant quantity of memory  $C$  cells in the lungs ([18]). The  
23 major part of the antigen-specific memory effector  $C$  cells no longer divides in the lung. We  
24 will therefore consider that in the absence of any other stimulation, the probability  $p_C$  that a  
25  $C$  cell divide in the lamina propria is zero.

### 26 **2.4 Algorithm implementation**

27 Our algorithm (see section 2.1.10) is implemented in Julia, which allows to parallelize the  
28 computation sequences as well as to use graphic libraries, in order to produce drawings and



1 videos illustrating step by step the evolution of a starting situation according to the biological  
2 parameters selected to launch the simulations. Our program is modular, in the sense that it  
3 is made up of reusable functions for the benefit of users wishing to test other configurations  
4 involving different evolutionary laws. A complete version of the program can be downloaded  
5 from the following site :

6 <https://plmbox.math.cnrs.fr/d/49bcbc1db63a4654be7e>

## 7 **3 Results**

### 8 **3.1 Determination of parameters via biological information**

9 We will use the streamlined model for which a probabilistic analysis is possible to determine  
10 numerical values for the parameters  $\nu_0$ ,  $p_{dC}$ ,  $p_{dF}$ ,  $x_C$ ,  $x_F$ ,  $p_{istaC}$ ,  $p_{istaF}$ ,  $p_{iexaF}$  and  $N(iexaF)$   
11 for healthy subjects and patients with COPD. We will proceed in two steps. For each parameter  
12 considered, we will start by stating a mathematical property formulated in the framework of  
13 the streamlined model. Then, the use of biological data will allow to deduce a numerical value  
14 of the parameter which will be used for the simulations. For ease of reading, the proofs are  
15 pushed back to Section 5.

16 The numerical values of the different parameters in the streamlined model are presented in  
17 Table 2, see Section 6.

#### 18 **3.1.1 Determination of $p_{dC}$ , $p_{dC+}$ and $p_{dF}$**

19 We take into account that, for a healthy subject, the half-lives  $hl(C)$  and  $hl(F)$  of  $C$  and  $F$   
20 cells are known. Half-live is defined as the time required for the death of half a cell population.  
21 Thank to cell tracing experiments in animal models, this time is relatively easy to measure.  
22 Expressing the half-life of a cell as a function of its probability of dying over a 3mn-period is  
23 however non trivial, and is rigorously described below.

24 We consider a  $F$  cell at time 0 or a  $C$  cell at time 0 or just born. Let us note  $T(C)$  (resp.  
25  $T(F)$ ) the life time of a  $C$  (resp.  $F$ ) cell and  $q_{1/2}(T(C))$  (resp.  $q_{1/2}(T(F))$ ) its median. Recall  
26 that the median of a probability law is its quantile of order 1/2.

27 **Proposition 3.1** *We have*

$$\left\lfloor \frac{\ln 2}{\ln \{1/(1 - p_{dC})\}} \right\rfloor \leq q_{1/2}(T(C)) \leq 1 + \frac{\ln 2}{2(1 - p_{dC})^2} + \left\lfloor \frac{\ln 2}{\ln \{1/(1 - p_{dC})\}} \right\rfloor \quad (3.1)$$

$$\left\lfloor \frac{\ln 2}{\ln \{1/(1 - p_{dF})\}} \right\rfloor \leq q_{1/2}(T(F)) \leq 1 + \frac{\ln 2}{2(1 - p_{dF})^2} + \left\lfloor \frac{\ln 2}{\ln \{1/(1 - p_{dF})\}} \right\rfloor \quad (3.2)$$

28 where  $\lfloor x \rfloor$  is the greatest integer less than or equal to  $x$ .

Equation (3.1) (resp. (3.2)) gives a lower and an upper bound of the quantile of the half-life  
of a  $C$  (resp.  $F$ ) cell. It effectively allows to determine a value of  $p_{dC}$  (resp.  $p_{dC}$ ) as explained  
below. Indeed, it is known from the literature ([34] and [47]) that

$$hl^{ctl}(C) = 14 \text{ days} = 6\,720 \text{ time steps}, \quad hl^{ctl}(F) = 10 \text{ months} = 144\,000 \text{ time steps.} \quad (3.3)$$

We choose  $p_{dC}$  such that  $hl^{ctl}(C) = \frac{\ln 2}{\ln \{1/(1-p_{dC})\}}$  and  $p_{dF}$  so that  $hl^{ctl}(F) = \frac{\ln 2}{\ln \{1/(1-p_{dF})\}}$ , *i.e.*

$$p_{dC}^{ctl} = 1 - e^{-\ln 2/hl^{ctl}(C)} \approx 1.0 \times 10^{-4}, \quad p_{dF}^{ctl} = 1 - e^{-\ln 2/hl^{ctl}(F)} \approx 4.8 \times 10^{-6}. \quad (3.4)$$

For this choice of  $p_{dC}^{ctl}$  and  $p_{dF}^{ctl}$  we have :  $\frac{\ln 2}{2(1-p_{dC}^{ctl})^2} \approx 0.151$  and  $\frac{\ln 2}{2(1-p_{dF}^{ctl})^2} \approx 0.151$ .

We can thus deduce that the median of  $T(C)$  (resp.  $T(F)$ ) is reasonably close to  $hl^{ctl}(C)$  (resp.  $hl^{ctl}(F)$ ).

A study [49] suggests a modification of the  $C$  cell death processes in tissues from patients with COPD, with a decrease by about half of the percentage of apoptotic  $C$  cells in the distal airways of mild to moderate COPD patients, which constitute the majority of our study cohort. In patients with COPD, we will therefore choose for each  $C$  cell the probability  $p_{dC}^{COPD}$  of dying equal to

$$p_{dC}^{COPD} = p_{dC}^{ctl}/2 \approx 5 \times 10^{-5}. \quad (3.5)$$

Our previous work [7] showed that the exposure of fibrocytes to the secretions of the bronchial epithelia from patients with COPD decreases by a factor 2 the percentage of dead cells . Therefore we choose :

$$p_{dF}^{COPD} = p_{dF}^{ctl}/2 \approx 2.4 \times 10^{-6}. \quad (3.6)$$

In the streamlined model, which is a special case where local interactions play no role,  $\sigma$  is equal to 9 neighbors.

Studies show that lymphocyte cell death is increased by a factor 4 in a crowded environment ([45], [55]). We therefore choose :  $p_{dC+} = 4p_{dC}$ . We thus obtain :

$$p_{dC+}^{ctl} = 4p_{dC}^{ctl} \approx 4.0 \times 10^{-4}, \quad p_{dC+}^{COPD} = 4p_{dC}^{COPD} \approx 2.0 \times 10^{-4}. \quad (3.7)$$

### 1 3.1.2 Determination of $x_C$ and $x_F$

The parameters  $x_F$  and  $x_C$  are terms involved in the definition of respectively  $P_F(s, s')$  and  $P_C(s, s')$ , see (2.4) and (2.6). They are chosen such as the median speed of  $F$  and  $C$  cells is equal to  $2.3 \mu m/mn$ , as describe below.

Since  $C$  and  $F$  cells behave in a similar way, we will detail the following analysis only for  $F$  cells. Let  $\alpha > 0$  be a real number such that

$$\mathbb{P}(Y_\alpha \leq 4) = \frac{1}{2}, \quad \text{where } Y_\alpha \sim \mathcal{P}(\alpha). \quad (3.8)$$

It is easy to determine numerically the value of  $\alpha$ , we find  $\alpha \approx 4.67091$ .

Consider a  $F$  cell occupying the site  $s$  and which is alive and not completely surrounded. According to (2.4),  $F$  moves with probability  $p_{moveF} = 1 - k_F x_F$ . Since  $\alpha < 5$ , we can easily deduce from relation (2.5) that there is a unique  $x_F$  such that

$$p_{moveF} = 1 - k_F x_F = \frac{\alpha}{5} \approx 0.9342. \quad (3.9)$$

This leads to :

$$x_F = \frac{1 - \alpha/5}{\alpha/5} \left( \sum_{s' \in M(s)} f_F(V(C)(s')) 1_{\{s' \text{ empty}\}} \right), \quad k_F = \frac{\alpha/5}{\sum_{s' \in M(s)} f_F(V(C)(s')) 1_{\{s' \text{ empty}\}}}.$$

(3.10)

It is now possible to take into account the biological observation (2.8). During the  $15mn = 5 \times 3mn$  time intervals the  $F$  cell covers the distance of  $x_0 Z \mu m$  where  $Z = Z_k(\text{move}F) + \dots + Z_{k+4}(\text{move}F)$  is the number of moves between the time steps  $k+1$  and  $k+5$  (recall from Section 2.1.2 that  $x_0 = 7 \mu m$ ). It follows from Proposition 3.2 below that the law of  $Z$  is approximatively  $\mathcal{P}(\alpha)$ . The speed of  $F$  is thus  $V(\text{move}F) = \frac{x_0 Z}{15} \mu m/mn$ . Using (2.8) and (3.8) we get :

$$\mathbb{P}_{\nu_0}(V(\text{move}F) \leq v_0) = \mathbb{P}_{\nu_0}(Z \leq 4.93) = \mathbb{P}_{\nu_0}(Z \leq 4) = \frac{1}{2}.$$

Because the streamlined model is simple, we can give in Proposition 3.2 an accurate estimation of the law of  $Z$ . During a subperiod, if  $F$  is chosen, does not die and is completely surrounded, it cannot move, but we agree that it can have a virtual move with probability  $\alpha/5$ . We note  $Z_k(\text{move}F)$  (resp.  $Z'_k(\text{move}F)$ ) the number of real (resp. real and virtual) moves during the time-step  $k+1$ . It is interesting to introduce the random variable  $Z'_k(\text{move}F)$  since its law under  $\mathbb{P}_{\nu_0}^k$  is  $\mathcal{B}\left(N_k, \frac{(1-p_{dF})\alpha}{5N_k}\right)$ , where

$$\mathbb{P}_{\nu_0}^k \text{ is the conditional expectation given } X_k. \quad (3.11)$$

**Proposition 3.2** *We have :*

$$\mathbb{P}_{\nu_0}^k(Z_k(\text{move}F) \neq Z'_k(\text{move}F)) \leq \frac{1}{N_k} \mathbb{E}_{\nu_0}^k(\Gamma_k(F)) \quad (3.12)$$

- 1 where  $\Gamma_k$  is the number of times  $F$  is fully surrounded during the time step  $k+1$ .
- 2 We took  $k = 5$  years = 876 000 time periods, because we estimated that beyond this date
- 3 the stationary state is reached. We considered an additional period and we performed 100
- 4 simulations of this scheme. For each simulation,  $\Gamma_k(C) = \Gamma_k(F) = 0$  and the empirical mean
- 5 of the  $2/N_k$  is 0.015.
- 6 From (3.12) we deduce that the conditional law of the random variable  $Z_k(\text{move}F)$  is approxi-
- 7 matively  $\mathcal{B}\left(N_k, \frac{(1-p_{dF})\alpha}{5N_k}\right)$ . The distance between the binomial law  $\mathcal{B}(a, b)$  and the Poisson
- 8 distribution  $\mathcal{P}(ab)$  is lower than  $\delta = 2 \min(2, ab)b$  (see the Prohorov's inequality, section III.7
- 9 in [48]). In our case  $\delta \leq 2/N_k$ . Relations (3.4), (3.5) and (3.6) as well as our 100 simulations
- 10 imply that the binomial distribution  $\mathcal{B}\left(N_k, \frac{(1-p_{dF})\alpha}{5N_k}\right)$  can be accurately approximated by the
- 11 Poisson distribution  $\mathcal{P}(\alpha/5)$ .
- 12

**Remark 3.3** *For the  $C$  cells, there is a formula similar to (3.12) which is obtained by replacing the letter  $F$  by  $C$ . The real numbers  $x_C$  and  $k_C$  are given by*

$$x_C = \frac{1 - \alpha/5}{\alpha/5} \left( \sum_{s' \in M(s)} f_C(V(s')) 1_{\{s' \text{ empty}\}} \right), k_C = \frac{\alpha/5}{\sum_{s' \in M(s)} f_C(V(s')) 1_{\{s' \text{ empty}\}}}. \quad (3.13)$$

### 1 3.1.3 Determination of $p_{istaF}$ and $p_{istaC}$

Recall that according to Corollary 2.4, for  $k$  large enough

$$\mathbb{E}_{\nu_0}(N_k(C)) \approx \mathbb{E}_{\nu}(N_k(C)) = \mathbb{E}_{\nu}(N_0(C)), \quad \mathbb{E}_{\nu_0}(N_k(F)) \approx \mathbb{E}_{\nu}(N_k(F)) = \mathbb{E}_{\nu}(N_0(F)) \quad (3.14)$$

2 where  $\nu$  is the invariant probability.

3 However, the mean equilibrium values  $\mathbb{E}_{\nu}(N_0(C))$  and  $\mathbb{E}_{\nu}(N_0(F))$  are unknown. We will select  
 4  $p_{istaC}$  (resp.  $p_{istaF}$ ) as a function of  $p_{dC}$  and  $N_0(C)$  (resp.  $p_{dF}$  and  $N_0(F)$ ) in such a way that  
 5 the number of  $C$  (resp.  $F$ ) cells is close to  $N_0(C)$  (resp.  $N_0(F)$ ) at equilibrium. This result is  
 6 based on a calculation of the expectation of  $N_k(C)$  (resp.  $N_k(F)$ ) in terms of  $k$  and the model  
 7 parameters.

8 **Proposition 3.4** *We suppose that there is no infiltration during exacerbations, i.e.  $N(iexaF) =$   
 9  $p_{iexaF} = 0$ . Then for any  $k$  we have :*

$$\mathbb{E}_{\nu_0}(N_k(C)) = \left( N_0(C) - \frac{p_{istaC}}{p_{dC}} \right) (1 - p_{dC})^k + \frac{p_{istaC}}{p_{dC}} + \epsilon_k^C \quad (3.15)$$

$$\mathbb{E}_{\nu_0}(N_k(F)) = \left( N_0(F) - \frac{p_{istaF}}{p_{dF}} \right) (1 - p_{dF})^k + \frac{p_{istaF}}{p_{dF}} + \epsilon_k^F \quad (3.16)$$

where  $\epsilon_k^C$  and  $\epsilon_k^F$  are positive numbers such that

$$\epsilon_k^C \leq \frac{p_{dC}}{2} \left( \frac{p_{istaC}}{p_{dC}(1 - p_{dC}/2)} + N_0(C) \right), \quad \epsilon_k^F \leq \frac{p_{dF}}{2} \left( \frac{p_{istaF}}{p_{dF}(1 - p_{dF}/2)} + N_0(F) \right). \quad (3.17)$$

**Remark 3.5** 1. Since  $\lim_{k \rightarrow \infty} (1 - p_{dC})^k = 0$  (resp  $\lim_{k \rightarrow \infty} (1 - p_{dF})^k = 0$ ), then under the  
 assumption that  $p_{dC}$  (resp.  $p_{dF}$ ) is small, the general formula (3.15) (resp. (3.16))  
 implies

$$\mathbb{E}_{\nu_0}(N_k(C)) \approx \frac{p_{istaC}}{p_{dC}}, \quad \left( \text{resp. } \mathbb{E}_{\nu_0}(N_k(F)) \approx \frac{p_{istaF}}{p_{dF}} \right) \quad \text{for } k \text{ large enough.}$$

2. For healthy patients, we want to determine the parameters  $p_{istaC}$  and  $p_{istaF}$  in such  
 a way that  $k \mapsto N_k(C)$  and  $k \mapsto N_k(F)$  fluctuate little (at least at equilibrium) and  
 remain close to  $N_0(C)$  and  $N_0(F)$  respectively. This leads us to take :

$$p_{istaC}^{ctl} = p_{dC}^{ctl} N_0(C) = 1.18 \times 10^{-2}, \quad p_{istaF}^{ctl} = p_{dF}^{ctl} N_0(F) = 9.12 \times 10^{-5}. \quad (3.18)$$

10 We easily deduce that we have achieved our goal :  $\mathbb{E}_{\nu_0}(N_k(C)) \approx N_0(C)$  and  $\mathbb{E}_{\nu_0}(N_k(F)) \approx$   
 11  $N_0(F)$ , for  $k$  large enough.

12 3. In practice, in the COPD case, we choose to keep the relation  $p_{istaC}^{COPD} = p_{dC}^{COPD} N_0(C)$   
 13 and as  $p_{dC}$  is different in patients with COPD than in healthy subjects (cf (3.5)), we  
 14 obtain  $p_{istaC}^{COPD} = p_{istaC}^{ctl} / 2 = 5.9 \times 10^{-3}$ .

15 The case of  $F$  cells is analogous, we choose  $p_{istaF}^{COPD} = p_{dF}^{COPD} N_0(F)$ . Relation (3.6)  
 16 leads to  $p_{istaF}^{COPD} = p_{istaF}^{ctl} / 2 = 4.56 \times 10^{-5}$ .

17 Therefore the average number of  $C$  (resp.  $F$ ) cells, not counting those added by exacer-  
 18 bation, is close to  $N_0(C)$  (resp.  $N_0(F)$ ).

1 **3.1.4 Determination of  $N(\textit{ie}xaF)$  and  $p_{\textit{ie}xaF}$  for COPD patients**

For simplification, we will assume that there is no  $C$  cell infiltration during exacerbations. Then  $p_{\textit{ie}xaC} = 0$ . Thus, for healthy subjects as well as for patients with COPD  $p_{\textit{ie}xaC}^{ctl} = p_{\textit{ie}xaC}^{COPD} = 0$ . Concerning  $F$  cells, the value of  $p_{\textit{ie}xaF}$  depends closely on the condition of the subject. For a healthy subject, as there is no exacerbation, this probability is zero :  $p_{\textit{ie}xaF}^{ctl} = 0$ . For patients with COPD, we add  $N_{\textit{ie}xaF}$   $F$  cells with probability  $p_{\textit{ie}xaF}$  every year, which is the average exacerbation frequency of patients with COPD. Recall that we have made the same assumption as for stable infiltration : if we add  $N_{\textit{ie}xaF}$   $F$  cells at the beginning of a year, these cells are not active immediately and they have to wait for the next time step before being active. In agreement with *in situ* measurements ([7]) the average number of  $F$ , after  $T$  time steps (i.e. 20 years), must be twice the number of  $F$  cells for a healthy subject. According to item 2 of Remark 3.5, for an healthy subject, the expected number of  $F$  cells is close to the initial number  $N_0(F)$  of  $F$  cells. Therefore the goal is to determine  $p_{\textit{ie}xaF}$  and  $N(\textit{ie}xaF)$  such that

$$\mathbb{E}_{\nu_0}(N_T(F)) = 2N_0(F). \quad (3.19)$$

2 Let us introduce the real numbers  $K_1$ ,  $K_2$  and  $R'$  :

$$K_1 = (1 - (1 - p_{dF})^{T_y}) \left( 2N_0(F) - (1 - p_{dF})^T \left( N_0(F) - \frac{p_{\textit{ista}F}}{p_{dF}} \right) - \frac{p_{\textit{ista}F}}{p_{dF}} \right) \quad (3.20)$$

$$K_2 = (1 - p_{dF})^{T_y - 1} (1 - (1 - p_{dF})^T). \quad (3.21)$$

and

$$R' = \frac{1}{1 - (1 - p_{dF})^{T_y}} \left\{ \frac{p_{\textit{ista}F}}{2(1 - p_{dF}/2)} + \frac{p_{dF}}{2} (p_{\textit{ista}F} + N(\textit{ie}xaF)p_{\textit{ie}xaF}) + \frac{p_{dF}(1 + p_{dF})}{2} \left[ N_0(F) + \left( \frac{p_{\textit{ista}F}}{p_{dF}} (1 - (1 - p_{dF})^{T_y}) \right) + (1 - p_{dF})^{T_y - 1} N(\textit{ie}xaF)p_{\textit{ie}xaF} + \frac{p_{\textit{ista}F}}{2(1 - p_{dF}/2)} + \frac{p_{dF}}{2} (p_{\textit{ista}F} + N(\textit{ie}xaF)p_{\textit{ie}xaF}) \right] \frac{1}{1 - (1 - p_{dF})^{T_y} - p_{dF}(1 + p_{dF})/2} \right\}. \quad (3.22)$$

**Proposition 3.6** We choose :

$$N(\textit{ie}xaF) = \left\lfloor \frac{K_1}{K_2} \right\rfloor + 1 \quad (3.23)$$

and

$$p_{\textit{ie}xaF} = \frac{1}{N(\textit{ie}xaF)} \frac{K_1}{K_2} \quad (3.24)$$

where  $T_y = 175\ 200$  is the number of time steps in a year. Then

$$0 \leq \mathbb{E}_{\nu_0}(N_T(F)) - 2N_0(F) \leq R' \quad (3.25)$$

3 **Remark 3.7** 1.  $N(\textit{ie}xaF)$  is the smallest integer such that (3.24) holds.

2. Suppose that  $p_{\textit{ista}F} = p_{dF} N_0(F)$ , then

$$\frac{K_1}{K_2} = \frac{N_0(F)(1 - (1 - p_{dF})^{T_y})}{(1 - p_{dF})^{T_y - 1} (1 - (1 - p_{dF})^T)}.$$

3. According to item 3 of Remark 3.5,  $p_{istaF}^{COPD} = 4.56 \times 10^{-5}$ . Then  $p_{istaF}^{COPD} = p_{dF}^{COPD} N_0(F)$  and

$$N(iexaF) = 10, \quad p_{iexaF} \approx 0.993, \quad R' \approx 4.3 \times 10^{-4}.$$


1            Consequently, the expected number of  $F$  cells for COPD patients is reasonably close to  
2             $2N_0(F)$ .

### 3    3.2    Elements of simulation

4            Figure 3 shows the simulation results of fibrocytes and  $CD8+$  T cells behaviors within the  
5            peribronchial area during 20 years, for healthy subjects and patients with COPD, obtained  
6            with the streamlined model. Initial cell densities were scaled with respect to reference values,  
7            corresponding to the mean densities experimentally measured in non-smoking subjects. All  
8            results in Figure 3 have been obtained from the simulations. Figure 3A represents snapshots  
9            of the peribronchial area with fibrocytes, and  $CD8+$  T cells at the beginning and at the end of  
10            the simulations. The distributions of cells are non-uniform for healthy subjects as well as for  
11            COPD patients after 20 years (Figure 3A). An increased density of  $F$  cells as well as clusters  
12            of cells seems to be present in the sick condition (Figure 3A and movie 2). These properties  
13            are also visible on the movies 1 and 2. As these movies have been obtained 5 years after the  
14            beginning of the simulations, it shows that these particular repartitions are already present few  
15            years after the application of control or COPD dynamics. These movies also show important  
16            dynamic behavior, that would be difficult to reveal in any other way : some cells seem to form  
17            clusters, which are relatively dynamic structures. New clusters are formed during the 24h-time  
18            frame of the movies and others are dissolving, whereas some clusters seem relatively stable  
19            over the time frame, especially in the COPD situation.

20            Simulations allowed us to analyze the dynamics of cells over time. We represent in Figure 3B  
21            the fluctuations of  $k \rightarrow \overline{N(C)}_k$ , where  $\overline{N(C)}_k$  is the empirical mean of the number of  $C$  cells  
22            for the month  $k$ . They are close to 118 in the healthy condition, which is equal to the initial  
23            number of  $C$  cells ( $N_0(C) = 118$ ). It corroborates the theoretical results, showing that after  
24            a sufficient amount of time, the average number of  $C$  cells is close to  $N_0(C)$  (cf Remark 3.5).  
25            Similar findings are found in the COPD condition.

26            To characterize the importance of cell death and infiltration, we plotted the number of  $C$   
27            cells (resp  $F$  cells) that have died (Figure 3C, 3G) or infiltrated (Figure 3D, 3H) for each  
28            month. In agreement with experimental findings ([49]) taken into account in our model, cf  
29            (3.5), the death of  $C$  cells is reduced by two in COPD compared to control situation (Figure  
30            3C). In both situations, the infiltration of  $C$  cells compensates  $C$  cell death (Figure 3D-  
31            E). Furthermore, as expected, the number  $\overline{N(F)}_k$  doubles after 20 years, from the control  
32            (mean  $\overline{N(F)} = 20$ ) to the COPD condition (mean  $\overline{N(F)} = 40$ ) (Figure 3F). The change in  
33             $\overline{N(F)}_k$  in the COPD condition is mainly the consequence of the infiltration of  $F$  cells during  
34            exacerbations (Figure 3G-H), as shown by the cumulative numbers of  $F$  cells that have died  
35            and infiltrated (Figure 3I). This result was anticipated by our mathematical analysis, see  
36            Section 3.1.4, but the simulations allow us to show that the fluctuations are reasonable and  
37            seem to reproduce patients heterogeneity.



1

2 Figure 3. Simulation results of cell dynamics within the peribronchial area during 20 years,  
 3 for healthy subjects and patients with COPD, obtained with the streamlined model. **A**) Se-  
 4 lected representative pictures for control (top panels) and COPD (bottom panels) situations  
 5 at initial state (left panels) and after 20 years (right panels). CD8<sup>+</sup> T cells (*C* cells) and  
 6 fibrocytes (*F* cells) are represented respectively by pink and green squares. Panels surrounded  
 7 by grey : higher magnifications of peribronchial area. **B, F**) Graphs showing the time varia-  
 8 tions of  $x \rightarrow \overline{N(C)}_x$  in panel B (resp.  $x \rightarrow \overline{N(F)}_x$  in panel F), where  $\overline{N(C)}_x$  (resp.  $\overline{N(F)}_x$ )  
 9 is the empirical mean of the number of *C* (resp. *F*) cells for the month  $x$ . The average of  
 10  $\overline{N(C)}_x$  and  $\overline{N(F)}_x$  over the 20 years-period are indicated by red lines. **C, G**) Graphs show-  
 11 ing the variations of  $N_{x-1,x}(dC)$  (panel C) and  $N_{x-1,x}(dF)$  (panel G) over time.  $N_{x-1,x}(dC)$   
 12 and  $N_{x-1,x}(dF)$  are the number of *C* (resp. *F*) cells that have died for the month  $x$ . **D, H**)

1 Graphs showing the variations of  $N_{x-1,x}(iC)$  (panel D) and  $N_{x-1,x}(iF)$  (panel H) over time.  
2  $N_{x-1,x}(iC)$  and  $N_{x-1,x}(iF)$  are the number of  $C$  (resp.  $F$ ) cells that have infiltrated the per-  
3 ibronchial area for the month  $x$ . The infiltration at the stable state and during exacerbation  
4 are indicated respectively in blue and green. For control situation, there is no infiltration by  
5 exacerbation. **E, I**) Cumulative distributions of the numbers of  $C$  cells  $N_x(dC)$  and  $F$  cells  
6  $N_x(dF)$  that have died during the month  $x$  (red curve), and the numbers of  $C$  cells  $N_x(iC)$   
7 and  $F$  cells  $N_x(iF)$  that have infiltrated the surface of interest during the month  $x$  (blue  
8 curve).

### 9 **Movie legends**

10 Cell dynamics within the peribronchial area, 5 years after the beginning the initial time, images  
11 of the simulations were recorded every 3 min during 24 hours. CD8+ T cells ( $C$  cells) and  
12 fibrocytes ( $F$  cells) are represented respectively by pink and green squares.  
13 **Movie 1 (resp. 2)** : control (resp. COPD) situation.

## 14 **4 Conclusion and discussion**

15 In order to gain insights about the reasons for the breakdown of homeostasis that could  
16 emerge from slight deregulations of normal cellular processes in COPD, we developed a proba-  
17 bilistic cellular automaton mathematical model to replicate cell-scale properties of two different  
18 cell populations, fibrocytes and CD8+ T cells. It takes into account individual cell motility,  
19 death, proliferation and infiltration processes with rules that are dependent on the local mi-  
20 croenvironment. We assume that the diseased and healthy states are obtained for two distinct  
21 sets of parameters. We have introduced a simpler model in which one can mathematically  
22 compute probabilities of events or expectations of random variables of interest. This allowed  
23 to accurately derive the parameters according to biologically observations in human tissues  
24 and *in vitro* experiments. The results from the simulations suggest that modifications of the  
25 parameters are sufficient to generate an increased density of fibrocytes in the COPD situation  
26 compared to the healthy one, as well as different spatial distributions, which are consistent  
27 with *in situ* observations. This has not been achieved using any experimental approaches pre-  
28 viously.

29 Several assumptions were made to simplify this initial model. Parameters were estimated from  
30 biological data using the streamlined model, and their validity in the complete model is unk-  
31 nown. Our Markov model does not take into account memory effects, which could play a role  
32 in disease onset and evolution. In addition, cell interactions inside tissues are far more complex  
33 than those considered in this system. In particular, it does not take into account all the other  
34 cells, such as epithelial cells, smooth muscle cells and other immune cells. Long-range effects,  
35 such as the attractive effect of the bronchial epithelium at the lumen border could be included  
36 by assigning different displacement probabilities based on the distance to the inner edge of  
37 the grid. Nevertheless, our model seems to us to be a very good starting version that we may  
38 improve.

39 This model does not only propose causal explanations for *in situ* observations, but we also  
40 anticipate it to be predictive. Promising perspectives of this study include the ability to test  
41 the reversibility of the pathological state, as well as the efficacy and therapeutic window of a  
42 potential treatment for COPD.



## 1 5 Proofs of technical points

### 2 5.1 Proof of Proposition 3.1

3 Since the cells  $C$  and  $F$  play symmetrical roles, it is sufficient to consider a fixed  $C$  cell.  
 4 We start with two preliminary lemmas 5.1 and 5.3.

**Lemma 5.1** *Let  $D_k(C)$  be the event "C dies during  $N_k$  sub-time steps of the time step  $k+1$ ". Then*

$$P_{\nu_0}^{|k}(D_k(C)) = 1 - \left(1 - \frac{p_{dC}}{N_k}\right)^{N_k}. \quad (5.1)$$

and

$$p_{dC} - \frac{p_{dC}^2}{2} \leq P_{\nu_0}^{|k}(D_k(C)) \leq p_{dC}. \quad (5.2)$$

5 where  $P_{\nu_0}^{|k}$  has been defined by (3.11).

**Proof.** To simplify the notations we denote by  $\mathbb{P} = P_{\nu_0}^{|k}$ . Let  $B_j$  be the event : " $C$  is alive and does not die at the sub-time step  $j$ ",  $1 \leq j \leq N_k$ . Then,

$$\mathbb{P}(B_j | B_1 \cap \dots \cap B_{j-1}) = \frac{N_k - 1}{N_k} + \frac{1}{N_k}(1 - p_{dC}) = 1 - \frac{p_{dC}}{N_k}.$$

Reasoning by induction on  $j$ , we get :

$$\mathbb{P}(B_1 \cap \dots \cap B_j) = \left(1 - \frac{p_{dC}}{N_k}\right)^j, \quad 1 \leq j \leq N_k. \quad (5.3)$$

Since  $\overline{D_k(C)} = B_1 \cap \dots \cap B_{N_k}$ , then (5.1) follows. Inequality (5.2) is a consequence of

$$1 - \alpha x \leq (1 - x)^\alpha \leq 1 - \alpha x + \frac{\alpha(\alpha - 1)}{2}x^2, \quad 0 \leq x \leq 1, \alpha \geq 1. \quad (5.4)$$

6 ■

7 **Remark 5.2** *For a  $F$  cell, it is enough to change  $p_{dC}$  into  $p_{dF}$  and  $D_k(C)$  into  $D_k(F)$  in the*  
 8 *identities (5.1) and (5.2).*

9 The estimate provided by Lemma 5.1 will be used twice, in the proofs of Lemma 5.3 and  
 10 Proposition 3.4 (see Section 5.3).

11 Consider a  $C$  cell which is born at time step  $k_0 - 1$  and which starts to be active at time step  
 12  $k_0$ . Let  $T(C)$  be the lifetime of this cell, it is the first integer  $k \geq 1$  such that the  $C$  cell dies at  
 13 the time step  $k_0 - 1 + k$ . By definition  $T(C) \geq 1$ . The distribution of this variable is unknown.  
 14 However, thanks to (5.2), we can give an approximation of its distribution function.

**Lemma 5.3** *For any integer  $k \geq 0$ ,*

$$(1 - p_{dC})^k \leq \mathbb{P}_{\nu_0}(T(C) > k) \leq \left(1 - p_{dC} + \frac{p_{dC}^2}{2}\right)^k \quad (5.5)$$

**Proof.** Set  $n = k_0 - 1 + k$ , then

$$\mathbb{P}_{\nu_0}^n(T(C) > k + 1) = 1_{\{T(C) > k\}} \left(1 - \mathbb{P}_{\nu_0}^n(D_n(C))\right), \quad k \geq 0.$$

We take the expectation, using (5.2) we get :

$$(1 - p_{dC})\mathbb{P}_{\nu_0}(T(C) > k) \leq \mathbb{P}_{\nu_0}(T(C) > k + 1) \leq \left(1 - p_{dC} + \frac{p_{dC}^2}{2}\right)\mathbb{P}_{\nu_0}(T(C) > k).$$

1 The double inequality (5.5) is obtained by reasoning by recurrence on the integer  $k$ . ■

Recall that the median of a random variable  $Y$  with integer values is its quantile of order  $1/2$  :

$$q_{1/2}(Y) = \max \left\{ k \geq 1, \mathbb{P}(Y \leq k) \leq \frac{1}{2} \right\}.$$

**Lemma 5.4** *Let  $0 < a \leq b < 1$ , and  $Y$  be a random variable which takes its values in  $\{1, 2, \dots\}$  and such that :*

$$(1 - b)^k \leq \mathbb{P}(Y > k) \leq (1 - a)^k, \quad \forall k \geq 0. \quad (5.6)$$

Then

$$\left\lfloor \frac{\ln 2}{\ln(1/(1-b))} \right\rfloor \leq q_{1/2}(Y) \leq \left\lfloor \frac{\ln 2}{\ln(1/(1-a))} \right\rfloor. \quad (5.7)$$

**Proof.** For any  $0 < \rho < 1$ , we have :

$$n \geq \left\lfloor \frac{\ln 2}{\ln(1/\rho)} \right\rfloor + 1 \Leftrightarrow \rho^n < \frac{1}{2}. \quad (5.8)$$

We take  $\rho = 1 - a$  and  $k = \left\lfloor \frac{\ln 2}{\ln(1/\rho)} \right\rfloor + 1$ . Relations (5.6) and (5.8) imply

$$1 - \mathbb{P}(Y \leq k) = \mathbb{P}(Y > k) \leq \rho^k < \frac{1}{2} \Rightarrow \mathbb{P}(Y \leq k) > \frac{1}{2} \Rightarrow q_{1/2}(Y) < k.$$

Similarly, with  $\rho = 1 - b$  et  $k = \left\lfloor \frac{\ln 2}{\ln(1/\rho)} \right\rfloor$  we get :

$$1 - \mathbb{P}(Y \leq k) = \mathbb{P}(Y > k) \geq \rho^k \geq \frac{1}{2} \Rightarrow \mathbb{P}(Y \leq k) \leq \frac{1}{2} \Rightarrow k \leq q_{1/2}(Y).$$

2 ■

We now have all the elements to prove Proposition 3.1. We consider the relation (3.1) which only concerns the  $C$  cells. A direct use of inequalities (5.5) and (5.7) leads to :  $q_- \leq q_{1/2}(T(C)) \leq q_+$ , where :

$$q_- = \left\lfloor \frac{\ln 2}{\ln \left\{ 1/(1 - p_{dC}) \right\}} \right\rfloor, \quad q_+ = \left\lfloor \frac{\ln 2}{\ln \left\{ 1/(1 - p_{dC} + \frac{p_{dC}^2}{2}) \right\}} \right\rfloor.$$

By an easy calculation, we have :

$$q_+ - q_- \leq 1 + \frac{\ln 2}{\ln \left( 1 - p_{dC} + \frac{p_{dC}^2}{2} \right) \ln(1 - p_{dC})} \ln \left( 1 + \frac{p_{dC}^2}{2(1 - p_{dC})} \right).$$

3 To obtain (3.1), it is enough to use  $\ln(1 + x) < x$ , for any  $x > -1$ .

## 1 5.2 Proof of Proposition 3.2

If the  $F$  cell is never completely surrounded during time step  $k + 1$ , then  $Z_k(\text{move}F) = Z'_k(\text{move}F)$ . Otherwise, let us note  $i_1, \dots, i_r$  the sub-periods when the  $F$  cell is fully surrounded where  $r = \Gamma_k(F)$ . Note that  $Z_k(\text{move}F) = Z'_k(\text{move}F)$  means that there is no virtual move. Moreover the probability that a virtual shift occurs at time  $i_j$  is  $\frac{1}{N_k}(1 - p_{dF})\frac{\alpha}{5}$ . Consequently

$$\mathbb{P}_{\nu_0}^k \left( Z_k(\text{move}F) = Z'_k(\text{move}F) \mid i_1, \dots, i_r \right) = \left( 1 - \frac{1}{N_k}(1 - p_{dF})\frac{\alpha}{5} \right)^{\Gamma_k(F)}.$$

Using (5.4) we have :

$$\mathbb{P}_{\nu_0}^k (Z_k(\text{move}F) < Z'_k(\text{move}F)) \leq \frac{1}{N_k}(1 - p_{dF})\frac{\alpha}{5} \mathbb{E}_{\nu_0}^k(\Gamma_k(F)) \leq \frac{1}{N_k} \mathbb{E}_{\nu_0}^k(\Gamma_k(F)).$$

## 2 5.3 Proof of Proposition 3.4

3 We start with a lemma which will also be used in the proof of Proposition 3.6.

**Lemma 5.5** *Let  $0 < \lambda < a < 1$ ,  $\lambda_0 \geq 0$  and  $b > 0$ . We suppose that the two sequences of real numbers  $(x_n)_{n \geq 0}$  and  $(y_n)_{n \geq 1}$  satisfy*

$$x_{n+1} = (1 - a)x_n + b + y_{n+1}, \quad n \geq 0 \quad (5.9)$$

with  $x_0 \geq 0$  and

$$0 \leq y_{n+1} \leq \lambda_0 + \lambda x_n, \quad n \geq 0. \quad (5.10)$$

Then

$$x_n = \frac{b}{a} (1 - (1 - a)^n) + (1 - a)^n x_0 + \epsilon_n, \quad n \geq 0 \quad (5.11)$$

4 where  $\epsilon_0 = 0$  and for any  $n \geq 1$ ,

$$0 \leq \epsilon_n \leq \frac{1}{a} (1 - (1 - a)^n) \left( \lambda_0 + \lambda \left( \frac{b + \lambda_0}{a - \lambda} + x_0 \right) \right) \quad (5.12)$$

$$\leq \frac{1}{a} \left( \lambda_0 + \lambda \left( \frac{b + \lambda_0}{a - \lambda} + x_0 \right) \right). \quad (5.13)$$

**Proof.** We deduce from (5.9) and (5.10) :

$$x_{n+1} \leq (1 - a + \lambda)x_n + b + \lambda_0, \quad n \geq 0.$$

Note that  $0 < 1 - a + \lambda < 1$ . A direct induction reasoning allows to show

$$0 \leq x_n \leq \frac{b + \lambda_0}{a - \lambda} + x_0, \quad n \geq 0. \quad (5.14)$$

We suppose that (5.11) occurs and show that this equality is verified when  $n$  is changed into  $n + 1$ . Using both (5.9) and (5.10) we obtain :

$$x_{n+1} = \frac{b}{a} (1 - (1 - a)^{n+1}) + (1 - a)^{n+1} x_0 + \epsilon_{n+1}$$

where  $\epsilon_{n+1} = y_{n+1} + (1-a)\epsilon_n$ . We set  $\epsilon_0 = 0$ , a reasoning by recurrence allows to show

$$\epsilon_{n+1} = (1-a)^{n+1} \left( \sum_{k=0}^n \frac{y_{k+1}}{(1-a)^{k+1}} \right), \quad n \geq 1.$$

Relations (5.10) and (5.14) imply :

$$\epsilon_{n+1} \leq \lambda_0 \left[ \frac{1}{a} (1 - (1-a)^{n+1}) \right] + \lambda \left[ \left( \frac{b + \lambda_0}{a - \lambda} + x_0 \right) \times \frac{1}{a} (1 - (1-a)^{n+1}) \right].$$

1 This shows (5.12) where  $n$  is changed into  $n+1$ . ■

We only prove(3.16). According to the definition of the streamlined model :

$$\mathbb{E}_{\nu_0}^{|k} (N_{k+1}(F)) = N_k(F) + p_{istaF} - N_k(F) P_{\nu_0}^{|k} (D_k(F)).$$

We take the expectation on both sides, we get

$$\mathbb{E}_{\nu_0} (N_{k+1}(F)) = (1 - p_{dF}) \mathbb{E}_{\nu_0} (N_k(F)) + p_{istaF} + \theta_{k+1} \quad (5.15)$$

where  $\theta_{k+1} = \mathbb{E}_{\nu_0} \left[ \left( p_{dF} - P_{\nu_0}^{|k} (D_k(F)) \right) N_k(F) \right]$ . According to Lemma 5.1 :

$$0 \leq \theta_{k+1} \leq \frac{p_{dF}^2}{2} \mathbb{E}_{\nu_0} (N_k(F)).$$

Then applying Lemma 5.5 with  $x_k = \mathbb{E}_{\nu_0} (N_k(F))$  leads to

$$\mathbb{E}_{\nu_0} (N_k(F)) = \left( N_0(F) - \frac{p_{istaF}}{p_{dF}} \right) (1 - p_{dF})^k + \frac{p_{istaF}}{p_{dF}} + \epsilon_k \quad (5.16)$$

2 and  $0 \leq \epsilon_k \leq \frac{p_{dF}}{2} \left( \frac{p_{istaF}}{p_{dF}(1-p_{dF}/2)} + N_0(F) \right)$ .

### 3 5.4 Proof of Proposition 3.6

4 The proof of Proposition 3.6 is based on the two lemmas 5.6 and 5.7.

**Lemma 5.6** For any  $0 \leq i \leq 19$  :

$$\begin{aligned} \mathbb{E}_{\nu_0} (N_{(i+1)T_y}(F)) &= (1 - p_{dF})^{T_y} \mathbb{E}_{\nu_0} (N_{iT_y}(F)) + \frac{p_{istaF}}{p_{dF}} (1 - (1 - p_{dF})^{T_y}) \\ &\quad + (1 - p_{dF})^{T_y-1} N(iexaF) p_{iexaF} + \eta_{i+1} \end{aligned} \quad (5.17)$$

and

$$0 \leq \eta_{i+1} \leq \frac{p_{istaF}}{2(1 - p_{dF}/2)} + \frac{p_{dF}}{2} (p_{istaF} + N(iexaF) p_{iexaF}) + \frac{p_{dF}(1 + p_{dF})}{2} \mathbb{E}_{\nu_0} (N_{iT_y}(F)) \quad (5.18)$$

5 where one year equals  $T_y = 175\,200$  time steps.

**Proof.** 1) Let  $0 \leq i \leq 19$ . We start from (5.15) and (5.16) and apply Lemma 5.5 with  $x_k = \mathbb{E}_{\nu_0}(N_k(F))$  where  $iT_y + 1 \leq k \leq (i+1)T_y$  :

$$\mathbb{E}_{\nu_0}(N_{(i+1)T_y}(F)) = \frac{p_{istaF}}{p_{dF}}(1 - (1 - p_{dF})^{T_y-1}) + (1 - p_{dF})^{T_y-1} \mathbb{E}_{\nu_0}(N_{iT_y+1}(F)) + \epsilon_{T_y-1} \quad (5.19)$$

where

$$0 \leq \epsilon_{T_y-1} \leq \frac{p_{dF}}{2} \left( \frac{p_{istaF}}{p_{dF}(1 - p_{dF}/2)} + \mathbb{E}_{\nu_0}(N_{iT_y+1}^{COPOD}(F)) \right). \quad (5.20)$$

We add  $N(iexaF)$   $F$  cells with probability  $p_{iexaF}$ , at the end of the time step  $iT_y$ , reasoning as in the proof of Proposition 3.4, we have :

$$\mathbb{E}_{\nu_0}(N_{iT_y+1}(F)) = (1 - p_{dF}) \mathbb{E}_{\nu_0}(N_{iT_y}(F)) + p_{istaF} + N(iexaF)p_{iexaF} + \theta_1 \quad (5.21)$$

where

$$0 \leq \theta_1 \leq \frac{(p_{dF})^2}{2} \mathbb{E}_{\nu_0}(N_{iT_y}(F)). \quad (5.22)$$

Synthesizing (5.19) and (5.21) we obtain (5.17) and  $0 \leq \eta_{i+1} = (1 - p_{dF})^{T_y-1} \theta_1 + \epsilon_{T_y-1} \leq \theta_1 + \epsilon_{T_y-1}$ .

Using (5.20), (5.21) and (5.22) we obtain :

$$\epsilon_{T_y-1} \leq \frac{p_{istaF}}{2(1 - p_{dF}/2)} + \epsilon^*$$

1 where

$$\begin{aligned} \epsilon^* &= \frac{p_{dF}}{2} \left[ (1 - p_{dF}) \mathbb{E}_{\nu_0}(N_{iT_y}(F)) + p_{istaF} + N(iexaF)p_{iexaF} + \theta_1 \right] \\ &\leq \frac{p_{dF}}{2} \left[ p_{istaF} + N(iexaF)p_{iexaF} + \mathbb{E}_{\nu_0}(N_{iT_y}(F)) \right]. \end{aligned}$$

2 Then inequality (5.18) follows directly. ■

**Lemma 5.7** We have :

$$\begin{aligned} \mathbb{E}_{\nu_0}(N_T(F)) &= \frac{p_{istaF}}{p_{dF}} + (1 - p_{dF})^T \left( N_0(F) - \frac{p_{istaF}}{p_{dF}} \right) \\ &\quad + \frac{(1 - p_{dF})^{T_y-1}}{1 - (1 - p_{dF})^{T_y}} (1 - (1 - p_{dF})^T) N(iexaF)p_{iexaF} + \epsilon'_{20} \end{aligned} \quad (5.23)$$

3 where  $0 \leq \epsilon'_{20} \leq R'$  and  $R'$  has been defined by (3.22).

**Proof.** We apply Lemme 5.5 with  $x_i = \mathbb{E}_{\nu_0}(N_{iT_y}(F))$  and  $0 \leq i \leq 20$  :

$$\begin{aligned} \mathbb{E}_{\nu_0}(N_T(F)) &= (1 - p_{dF})^T \left( N_0(F) - \frac{p_{istaF}}{p_{dF}} - \frac{(1 - p_{dF})^{T_y-1}}{1 - (1 - p_{dF})^{T_y}} N(iexaF)p_{iexaF} \right) \\ &\quad + \frac{p_{istaF}}{p_{dF}} + \frac{(1 - p_{dF})^{T_y-1}}{1 - (1 - p_{dF})^{T_y}} N(iexaF)p_{iexaF} + \epsilon'_{20} \end{aligned}$$

4 This shows (5.23). Moreover  $0 \leq \epsilon'_{20} \leq R'$ . ■

We apply (5.23) and (3.24), we easily obtain :

$$\mathbb{E}_{\nu_0}(N_T(F)) = 2N_0(F) + \epsilon'_{20}.$$

5 This implies (3.25).

## 1 6 Annex

2 Table 1. Definition of the notations and parameters of the model

3

	Symbols	Meanings
Surface of interest	$\mathcal{L}$	Lamina propria (=peribronchial area)
	$x_0$	Side length of the units of the lattice $\mathcal{L}$
General	$M(s)$	Neighbourhood of the site $s$
	$V(s)$	Number of $F$ and $C$ cells belonging to $M(s)$
	$V(F)(s)$	Number of $F$ cells belonging to $M(s)$
	$V(C)(s)$	Number of $C$ cells belonging to $M(s)$
	$N_k(F)$	Number of $F$ cells at the beginning of the time step $k$
	$N_k(C)$	Number of $C$ cells at the beginning of the time step $k$
Cell death	$p_{dF}$	Probability for a $F$ cell to die
	$p_{dC}$	Probability for a $C$ cell to die
	$p_{dC+}$	Increased probability for a $C$ cell to die
	$\sigma$	Threshold number of neighbouring $C$ cells, above which the probability of dying is increased from $p_{dC}$ to $p_{dC+}$
Cell proliferation	$p_F$	Probability for a $F$ cell to divide
	$p_C$	Probability for a $C$ cell to divide
	$p_{C/F}$	Increased probability for a $C$ cell to divide
	$\lambda$	Threshold number of neighbouring $C$ cells of an empty $s'$ site belonging to $M(s)$ , above which the considered $C$ cell does not divide

4

5

Cell displacement	$P_F(s, s')$	Probability for a $F$ cell to go from $s$ to $s'$
	$P_C(s, s')$	Probability for a $C$ cell to go from $s$ to $s'$
	$f_F$	Function that is involved in the definition of $P_F(s, s')$ and which is applied to $V_C(F)(s')$ where $s'$ is empty, $s' \neq s$ and $s' \in M(s)$
	$f_C$	Function that is involved in the definition of $P_C(s, s')$ and which is applied to $V(s')$ where $s'$ is empty, $s' \neq s$ and $s' \in M(s)$
	$\epsilon_F$	Value taken by $f_F$ to reflect a low attraction
	$\epsilon_C$	Value taken by $f_C$ to reflect a low attraction
Cell infiltration	$p_{istaF}$	Probability for a $F$ cell to get infiltrated at the beginning of a 3 minutes time step
	$p_{istaC}$	Probability for a $C$ cell to get infiltrated at the beginning of a 3 minutes time step
	$p_{iexaF}$	Probability for a $F$ cell to get infiltrated during an exacerbation
	$p_{iexaC}$	Probability for a $C$ cell to get infiltrated during an exacerbation
	$N(iexaF)$	Number of $F$ cell that are infiltrated during an exacerbation
	$N(iexaC)$	Number of $C$ cell that are infiltrated during an exacerbation

2 Table 2. Numerical values of the streamlined model parameters depending in control and  
3 COPD situations

Symbols	$x_0$	$N_0(F)$	$N_0(C)$	$p_{dF}^{ctl}$	$p_{dF}^{COPD}$	$p_{dC}^{ctl}$	$p_{dC}^{COPD}$
Numerical values	$7 \mu m$	19	118	$4.8 \times 10^{-6}$	$2.4 \times 10^{-6}$	$10^{-4}$	$5 \times 10^{-5}$

Symbols	$p_{dC+}^{ctl}$	$p_{dC+}^{COPD}$	$\sigma$	$p_F$	$p_C$	$p_{C/F}^{ctl} = p_{C/F}^{COPD}$	$\lambda$	$\epsilon_F = \epsilon_C$
Numerical values	$4 \times 10^{-4}$	$2 \times 10^{-4}$	9	0	0	$1.25 \times 10^{-2}$	0	$10^{-3}$

Symbols	$p_{istaF}^{ctl}$	$p_{istaF}^{COPD}$	$p_{istaC}^{ctl}$	$p_{istaC}^{COPD}$	$p_{iexaF}^{ctl}$	$p_{iexaF}^{COPD}$
Numerical values	$9.12 \times 10^{-5}$	$4.56 \times 10^{-5}$	$1.18 \times 10^{-2}$	$5.9 \times 10^{-3}$	0	$9.93 \times 10^{-1}$

Symbols	$p_{iexaC}^{ctl} = p_{iexaC}^{COPD}$	$N(iexaF)^{ctl}$	$N(iexaF)^{COPD}$	$N(ixaC)$
Numerical values	0	0	10	0

## References

- [1] T. Afroj, A. Mitsuhashi, Ogino H., A. Saijo, K. Otsuka, H. Yoneda, M. Tobiume, N.T. Nguyen, H. Goto, K. Koyama, M. Sugimoto, O. Kondoh, H. Nokihara, and Y. Nishioka. Blockade of pd-1/pd-l1 pathway enhances the antigen-presenting capacity of fibrocytes. *J. Immunol.*, 206(6) :1204–1214, 2021.
- [2] M. C. Basil, F. L. Cardenas-Diaz, J. J. Kathiriya, M. P. Morley, J. Carl, A. N. Brumwell, J. Katzen, K. J. Slovik, A. Babu, S. Zhou, M. M. Kremp, K. B. McCauley, S. Li, J. D. Planer, S. S. Hussain, X. Liu, R. Windmueller, Y. Ying, K. M. Stewart, M. Oyster, and E. E. Morrissey. Human distal airways contain a multipotent secretory cell that can regenerate alveoli. *Nature*, 604(7904) :120–126, 2022.
- [3] L. Benítez, L. Barberis, and C.A. Condat. Modeling tumorspheres reveals cancer stem cell niche building and plasticity. *Physica A : Statistical Mechanics and its Applications*, 533 :121906, 2019.
- [4] Y. W. Chen, J. M. Leung, and D. D. Sin. A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation. *PLoS One*, 11(7) :e0158843, 2016.
- [5] A. Deutsch and S. Dormann. *Cellular automaton modeling of biological pattern formation*. Modeling and Simulation in Science, Engineering and Technology. Birkhäuser/Springer, New York, 2017. Characterization, examples, and analysis, Second edition.
- [6] I. Dupin, B. Allard, A. Ozier, E. Maurat, O. Ousova, E. Delbrel, T. Trian, H.-N. Bui, C. Dromer, O. Guisset, E. Blanchard, G. Hilbert, F. Vargas, M. Thumerel, R. Marthan, P.-O. Girodet, and P. Berger. Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a cxcr4-dependent pathway. *J. Allergy Clin. Immunol.*, 137 :1036–1042, 2016.
- [7] I. Dupin, M. Thumerel, E. Maurat, F. Coste, E. Eyraud, H. Begueret, T. Trian, M. Montaudon, R. Marthan, P.-O. Girodet, and P. Berger. Fibrocyte accumulation in the airway walls of copd patients. *Eur. Respir. J.*, 54, 2019.
- [8] K. H. Ely, T. Cookenham, A. D. Roberts, and D. L. Woodland. Memory T cell populations in the lung airways are maintained by continual recruitment. *J Immunol*, 176(1) :537–543, Jan 2006.
- [9] C. M. Freeman, C. H. Martinez, J. C. Todt, F. J. Martinez, M. K. Han, D. L. Thompson, L. McCloskey, and J. L. Curtis. differentiation factor-15 (GDF-15) in peripheral blood. *Respir Res*, 16 :94, Aug 2015.
- [10] S. Ghosh and S. Bhattacharya. Computational model on covid-19 pandemic using probabilistic cellular automata. *SN Computer Science*, 2021.
- [11] D.A. Groneberg and Chung K.F. Models of chronic obstructive pulmonary disease. *Respir Res.*, 5(1) :18, 2004.
- [12] E. J. Hackett-Jones, K. A. Landman, D. F. Newgreen, and D. Zhang. On the role of differential adhesion in gangliogenesis in the enteric nervous system. *J. Theor. Biol.*, 287 :148–159, 2011.



- 1 [13] O. Häggström. Finite Markov chains and algorithmic applications, volume 52 of London  
2 Mathematical Society Student Texts. Cambridge University Press, Cambridge, 2002.
- 3 [14] N. L. Harris, V. Watt, F. Ronchese, and G. Le Gros. Differential T cell function and fate  
4 in lymph node and nonlymphoid tissues. J Exp Med, 195(3) :317–326, Feb 2002.
- 5 [15] M. Hasegawa, Y. Nasuhara, Y. Onodera, H. Makita, K. Nagai, S. Fuke, Y. Ito, T. Bet-  
6 suyaku, and M. Nishimura. Airflow limitation and airway dimensions in chronic obstructive  
7 pulmonary disease. Am. J. Respir. Crit. Care Med., 173 :1309–1315, 2006.
- 8 [16] H. Hatzikirou, L. Brusch, C. Schaller, M. Simon, and A. Deutsch. Prediction of traveling  
9 front behavior in a lattice-gas cellular automaton model for tumor invasion. Comput.  
10 Math. Appl., 59(7) :2326–2339, 2010.
- 11 [17] H. D. Hickman, G. V. Reynoso, B. F. Ngudiankama, S. S. Cush, J. Gibbs, J. R. Bennink,  
12 and J. W. Yewdell. CXCR3 chemokine receptor enables local CD8(+) T cell migration  
13 for the destruction of virus-infected cells. Immunity, 42(3) :524–537, Mar 2015.
- 14 [18] R.J. Hogan, L.S. Cauley, K.H. Ely, T. Cookenham, A.D. Roberts, J.W. Brennan, S. Mo-  
15 nard, and D.L. Woodland. Long-term maintenance of virus-specific effector memory cd8+  
16 t cells in the lung airways depends on proliferation. J. Immunol., 169 :4976–4981, 2002.
- 17 [19] P. Hogeweg. Cellular automata as a paradigm for ecological modeling. Appl. Math.  
18 Comput., 27(1) :81–100, 1988.
- 19 [20] J.C. Hogg, F. Chu, S. Utokaparch, R. Woods, W.M. Elliott, L. Buzatu, R.M. Cherniack,  
20 R.M. Rogers, F.C. Scirba, H.O. Coxson, and P.D. Paré. The nature of small-airway  
21 obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med., 350 :2645–2653,  
22 2004.
- 23 [21] J. R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerova, R. Tal-Singer, B. Miller,  
24 D. A. Lomas, A. Agusti, W. Macnee, P. Calverley, S. Rennard, E. F. Wouters, J. A.  
25 Wedzicha, H. Coxson, L. Edwards, R. Tal-Singer, D. Lomas, W. MacNee, E. Silverman,  
26 C. Crim, J. Vestbo, J. Yates, A. Agusti, P. Calverley, B. Celli, C. Crim, B. Miller, W. Mac-  
27 Nee, S. Rennard, R. Tal-Singer, E. Wouters, J. Yates, Y. Ivanov, K. Kostov, J. Bourbeau,  
28 M. Fitzgerald, P. Hernandez, K. Killian, R. Levy, F. Maltais, D. O’Donnell, J. Krepelka,  
29 J. Vestbo, E. Wouters, D. Quinn, P. Bakke, M. Kosnik, A. Agusti, J. Saulea, Y. Fes-  
30 chenko, V. Gavrisyuk, L. Yashina, N. Monogarova, P. Calverley, D. Lomas, W. Mac-  
31 Nee, D. Singh, J. Wedzicha, A. Anzueto, S. Braman, R. Casaburi, B. Celli, G. Giessel,  
32 M. Gotfried, G. Greenwald, N. Hanania, D. Mahler, B. Make, S. Rennard, C. Rochester,  
33 P. Scanlon, D. Schuller, F. Scirba, A. Sharafkhaneh, T. Siler, E. Silverman, A. Wan-  
34 ner, R. Wise, and R. ZuWallack. Susceptibility to exacerbation in chronic obstructive  
35 pulmonary disease. N Engl J Med, 363(12) :1128–1138, Sep 2010.
- 36 [22] M. Karakioulaki, E. Papakonstantinou, and D. Stolz. Extracellular matrix remodelling  
37 in COPD. Eur Respir Rev, 29(158), Dec 2020.
- 38 [23] D.I. Krimmer and B. G. Oliver. What can in vitro models of copd tell us? Pulmonary  
39 pharmacology & therapeutics, 24(5) :471–477, 2011.
- 40 [24] R. L. Kusko, J. F. Brothers, J. Tedrow, K. Pandit, C. Huleihel, L.and Perdomo, B.and  
41 Kass D. Liu, G.and Juan-Guardela, M.and Martinez F. Zhang, S.and Lenburg, J. Qua-  
42 ckenbush, A.and Geraci M. Scirba, F.and Limper, Yang, D. A. I., Schwartz, A. Beane,  
43 J.and Spira, and N. Kaminski. Integrated genomics reveals convergent transcriptomic  
44 networks underlying chronic obstructive pulmonary disease and idiopathic pulmonary fi-  
45 brosis. American journal of respiratory and critical care medicine, 194(8) :948–960, 2016.

- 1 [25] K. A. Landman and D. F. Newgreen. PCA modelling of multi-species cell clusters :  
2 ganglion development in the gastrointestinal nervous system. In Probabilistic cellular  
3 automata, volume 27 of Emerg. Complex. Comput., pages 261–277. Springer, Cham,  
4 2018.
- 5 [26] C. Launay, B. Galerne, and A. Desolneux. Exact sampling of determinantal point pro-  
6 cesses without eigendecomposition. J. Appl. Probab., 57(4) :1198–1221, 2020.
- 7 [27] C.W. Lawrence and T.J. Braciale. Activation, differentiation, and migration of naive  
8 virus-specific cd8+ t cells during pulmonary influenza virus infection. J. Immunol.,  
9 173 :1209–1218, 2004.
- 10 [28] D. Lehotzky, R. Sipahi, and G. Zupanc. Cellular automata modeling suggests symmetric  
11 stem-cell division, cell death, and cell drift as key mechanisms driving adult spinal cord  
12 growth in teleost fish. Journal of Theoretical Biology, 509 :22, 2021.
- 13 [29] C. Ling, K. Nishimoto, Z. Rolfs, L. M. Smith, B. L. Frey, and N. V. Welham. Differentiated  
14 fibrocytes assume a functional mesenchymal phenotype with regenerative potential. Sci  
15 Adv, 5(5) :eaav7384, 05 2019.
- 16 [30] P.-Y. Louis and F. R. Nardi, editors. Probabilistic cellular automata. Theory, applications  
17 and future perspectives, volume 27. Springer, 2018.
- 18 [31] A. Løkke, P. Lange, H. Scharling, P. Fabricius, and J. Vestbo. Developing COPD : a 25  
19 year follow up study of the general population. Thorax, 61(11) :935–939, Nov 2006.
- 20 [32] H. Mahmoud and A. Chulahwat. A probabilistic cellular automata framework for as-  
21 sessing the impact of wui fires on communities. Procedia Engineering, 198 :1111–1122,  
22 2017.
- 23 [33] L. Manukyan, S. A. Montandon, A. Fofonjka, S. Smirnov, and M. C. Milinkovitch. A  
24 living mesoscopic cellular automaton made of skin scales. Nature, 544(7649) :173–179,  
25 04 2017.
- 26 [34] S.R. McMaster, J.J. Wilson, H. Wang, and J.E. Kohlmeier. Airway-resident memory  
27 cd8 t cells provide antigen-specific protection against respiratory virus challenge through  
28 rapid ifn-production. J. Immunol., 195 :203–209, 2015.
- 29 [35] P. Mrass, S.R. Oruganti, G.M. Fricke, J. Tafoya, J.R. Byrum, L. Yang, S.L. Hamilton,  
30 M.J. Miller, M.E. Moses, and J.L. Cannon. Rock regulates the intermittent mode of  
31 interstitial t cell migration in inflamed lungs. Nat. Commun., 2017.
- 32 [36] J. M. Nava-Sedeño, H. Hatzikirou, F. Peruani, and A. Deutsch. Extracting cellular au-  
33 tomaton rules from physical Langevin equation models for single and collective cell mi-  
34 gration. J. Math. Biol., 75(5) :1075–1100, 2017.
- 35 [37] T. C. O’Shaughnessy, T. W. Ansari, N. C. Barnes, and P. K. Jeffery. Inflammation  
36 in bronchial biopsies of subjects with chronic bronchitis : inverse relationship of cd8+  
37 t lymphocytes with fev1. American journal of respiratory and critical care medicine,  
38 155(3) :852–857, 1997.
- 39 [38] F. Peruani, A. Deutsch, and M. Bär. A mean-field theory for self-propelled particles  
40 interacting by velocity alignment mechanisms. The European Physical Journal Special  
41 Topics, 157 :111–122, 2008.
- 42 [39] J. J. Pothen, M. E. Poynter, and J. H. Bates. The inflammatory twitch as a general  
43 strategy for controlling the host response. Journal of Immunology (Baltimore, Md. :  
44 1950), 190(7) :3510–3516, 2013.

- 1 [40] J. J. Pothen, M. E. Poynter, and J. H. Bates. A computational model of unresolved  
2 allergic inflammation in chronic asthma. American Journal of Physiology. Lung Cellular  
3 and Molecular Physiology, 308(4) :384–390, 2015.
- 4 [41] J. G. Propp and D. B. Wilson. Exact sampling with coupled Markov chains and appli-  
5 cations to statistical mechanics. In Proceedings of the Seventh International Conference  
6 on Random Structures and Algorithms (Atlanta, GA, 1995), volume 9, pages 223–252,  
7 1996.
- 8 [42] M. Puljic and R. Kozma. Narrow-band oscillations in probabilistic cellular automata.  
9 Phys. Rev. E, 78 :026214, Aug 2008.
- 10 [43] M. Saetta, A. Di Stephano, G. Turato, F.M. Facchini, L. Corbino, C.E. Mapp, P. Maes-  
11 trelli, A. Ciaccia, and L.M. Fabbri. Cd8+ t-lymphocytes in peripheral airways of smokers  
12 with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 157 :822–826,  
13 1998.
- 14 [44] R. Saunders, H. Kaul, R. Berair, S. Gonem, A. Singapuri, A. J. Sutcliffe, L. Chachi, M. S.  
15 Biddle, D. Kaur, M. Bourne, I. D. Pavord, A. J. Wardlaw, S. H. Siddiqui, R. A. Kay,  
16 B. S. Brook, R. H. Smallwood, and C. E. Brightling. Antagonism reduces airway smooth  
17 muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Sci  
18 Transl Med, 11(479), 02 2019.
- 19 [45] P. Scheipers and H. Reiser. Fas-independent death of activated cd4+ t lymphocytes  
20 induced by ctla-4 crosslinking. Proc. Natl. Acad. Sci., 95 :10083–10088, 1998.
- 21 [46] M. Schmidt, G. Sun, M. A. Stacey, L. Mori, and S. Mattoli. Identification of circulating  
22 fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol, 171(1) :380–  
23 389, Jul 2003.
- 24 [47] J. Schyns, Q. Bai, C. Ruscitti, C. Radermecker, S. De Schepper, S. Chakarov, F. Farnir,  
25 D. Pirottin, F. Ginhoux, G. Boeckxstaens, F. Bureau, and T. Marichal. Non-classical  
26 tissue monocytes and two functionally distinct populations of interstitial macrophages  
27 populate the mouse lung. Nat. Commun., 10, 2019.
- 28 [48] A. N. Shiriyayev. Probability, volume 95 of Graduate Texts in Mathematics. Springer-  
29 Verlag, New York, 1984. Translated from the Russian by R. P. Boas.
- 30 [49] L. Siena, M. Gjemarkaj, J. Elliot, E. Pace, A. Bruno, S. Baraldo, M. Saetta, M.R. Bonsi-  
31 gnore, and A. Jame. Reduced apoptosis of cd8+ t-lymphocytes in the airways of smokers  
32 with mild/moderate copd. Respir. Med., 105 :1491–1500, 2011.
- 33 [50] H.S. Silva and M.L. Martins. A cellular automata model for cell differentiation. Physica  
34 A : Statistical Mechanics and its Applications, 322 :555–566, 2003.
- 35 [51] S. Takamura, H. Yagi, Y. Hakata, C. Motozono, S. R. McMaster, T. Masumoto, M. Fu-  
36 jisawa, T. Chikaishi, J. Komeda, J. Itoh, M. Umemura, A. Kyusai, M. Tomura, T. Na-  
37 kayama, D. L. Woodland, J. E. Kohlmeier, and M. Miyazawa. Specific niches for lung-  
38 resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent  
39 maintenance. J Exp Med, 213(13) :3057–3073, 12 2016.
- 40 [52] A. van Haarst, L. McGarvey, and S Paglialunga. Review of drug development gui-  
41 dance to treat chronic obstructive pulmonary disease : Us and eu perspectives. Clinical  
42 pharmacology and therapeutics, 106(6) :1222–1235, 2019.
- 43 [53] Tamás Vicsek, András Czirók, Eshel Ben-Jacob, Inon Cohen, and Ofer Shochet. Novel  
44 type of phase transition in a system of self-driven particles. Phys. Rev. Lett., 75 :1226–  
45 1229, Aug 1995.

- 1 [54] H. Yoon, T.S. Kim, and T.J. Braciale. The cell cycle time of cd8+ t cells responding in  
2 vivo is controlled by the type of antigenic stimulus. PLoS ONE, 5, 2010.
- 3 [55] S. Zenke, M.M. Palm, J. Braun, A. Gavrillov, P. Meiser, J.P. J.P. Böttcher, N. Beyersdorf,  
4 S. Ehl, A. Gerard, T. Lämmermann, T.N. Schumacher, J.B. Beltman, and J.C. Rohr.  
5 Quorum regulation via nested antagonistic feedback circuits mediated by the receptors  
6 cd28 and ctla-4 confers robustness to t cell population dynamics. Immunity, 52 :313–327,  
7 2020.